The purpose of this study is to further characterize the immunophenotype of CNS germinomas with emphasis on the expression of CD117 (c-kit) in relation to possible mutations of the c-kit gene. Biopsy material from 20 CNS germinoma cases was studied immunohistochemically. In 10 cases, archived frozen tumor tissue was available for c-kit proto-oncogene mutation analysis. DNA extracted from regions with Ͼ80% tumor density underwent whole genome amplifi cation prior to mutation analysis. In one additional case, mutation analysis was performed on paraffi n-embedded tissue. Forward and reverse sequencing were performed on c-kit's exons 9, 11, 13, and 17. The neuroanatomical distribution of tumors is as follows: 10 pineal, six suprasellar, two thalamic, one basal ganglia, and one in the posterior third ventricle. There were 15 males and fi ve females, with an age average of 13.25 years and an age range of 7 to 17 years. The immunohistochemical profi le revealed strong positive staining for PLAP and CD117 in 100% of cases. The latter was always diffuse and stronger than PLAP. This difference was more accentuated in tissue frozen for intraoperative consultation and subsequently fi xed in formalin and processed routinely. HCG showed a weak diffuse cytoplasmic staining with few scattered strongly stained cells. AFP, CEA, and CD30 were consistently negative. Staining for vimentin and keratin reveal few scattered cells showing focal cytoplasmic staining. Molecular analysis for c-kit mutations showed 1/11 tumors with exon 17 (N822Y) mutation. This mutation represents gain-of-function mutation. We conclude that CD117 is a reliable immunohistochemical marker for germinomas. No relation between immunophenotype and mutations analysis was identifi ed. The 9% c-kit mutation rate in our study is consistent with previous reports of low frequency of c-kit mutations in germinomas. Intracranial germ cell tumors (CNSGCTs) constitute a group of neoplastic lesions which include teratoma, malignant germinoma, embryonal carcinoma, yolk sac tumors, and choriocarcinoma. The current treatment for CNSGCTs includes a combination of tumor resection, irradiation of the tumor cavity to prevent tumor spread, and craniospinal irradiation to control spread of the tumor to the leptomeninges. Chemotherapy is also used to prevent leptomeningeal and systemic tumor dissemination. Combination therapy, using cisplatin-based chemotherapy with radiation therapy, yielded promising results, achieving survival rates of 30% to 60%. Patients with progressive disease could benefi t from resection of the primary tumor. In these patients, a more aggressive treatment regime would be justifi ed, including high doses of chemotherapy with stem cell treatment. Since some patients do not develop metastatic disease, this highlights the importance of local tumor control using a combination of surgery, chemotherapy, and radiotherapy. In spite of the advances in patient's survival and improved treatment modalities, taking into account the side effects of both chemotherapy and radiotherapy, and also to improve outcomes in patients with disseminated disease, it is critical to develop new treatment strategies, such as stem or gene therapies. Gene therapy utilizes gene transfer vectors, such as viruses or plasmid DNA, to transfer therapeutic genes to target tissues or tumors. One of the most powerful viral vectors for gene transfer into the CNS is recombinant adenoviruses (RAds), which are currently being used in clinical trials for treating GBMs with very promising results (Trask et al., Mol. Ther. 1:195, 2000). RAds have also been used successfully in preclinical models of intracranial brain tumors (Dewey et al., Nat. Med. 5:1256, 1999; Ali et al., Mol. Ther. 10:1071, 2004. New generation RAds, deleted of all viral genes, can sustain long-term and stable therapeutic gene expression, even in the presence of a systemic antiadenovirus immune response as could be encountered in human patients (Thomas et al., PNAS 97:7482, 2000). We have recently shown that using a combination of suicide/ conditional cytotoxic (HSV1-TK plus ganciclovir) gene therapy together with the expression of the cytokine, soluble human fms-like tyrosine kinase (Flt3L), which generates a very powerful systemic immune response against the tumor, we can achieve cure in 80% of animals bearing large intracranial tumors. Importantly, the combined gene therapy elicited immunological memory, protecting the animals from a new tumor challenge. We propose that combining HSV1-TK with Flt3L adenoviral gene therapy may provide an effective adjuvant treatment modality for CNSGCTs in patients that present with disseminated disease. This work was funded by NIH/ NINDS 1RO1 NS44556.01, 1RO3 TW006273.01, 1RO1 NS42893.01, U54 NS045309.01, and 1R21 NS047298.01, the Linda Tallen and Paul Kane Foundation, and the BOG at CSMC.
Germinomas are rapidly proliferating tumors which disseminate widely within the central nervous system and are very radiation sensitive. For the past fi ve years, we have been working on a replication competent retrovirus (RCR) containing a variety of suicide genes including cytosine deaminase (CD), thymidine kinase (TK), purine nucleoside phosphorylase (PNP), and Egr-TNF (tumor necrosis factor). We have demonstrated that RCR is capable of selectively transducing glioma cells at a high frequency both in vitro and in vivo (Wang et al., Human Gene Ther. 14:117, 2003) . In vivo, RCR-CD has been used in intracranial glioma models (both immune deficient and immune competent) and has been shown to prolong survival by greater than 300% compared to nontreated animals (Tai et al., Mol. Ther., accepted, 2005) . RCR does not transduce normal brain cells and has been found capable of selectively tracking glioma cells that have invaded the normal brain. RCR could be an ideal gene therapy agent for treatment of germinomas because of its ability to selectively transduce dividing cells and track tumor cells throughout the central nervous system. Moreover, RCREgr-TNF could potentially be used in conjunction with radiation therapy, using radiation to activate the Egr promoter, leading to intratumoral secretion of TNF, and inducing a hemorrhagic radiation necrosis of the tumor. Because of the strong bystander effect, neighboring teratoma cells may also be killed at the same time. This new gene therapy technology may be applied to germinoma treatment in the near future.
*B4. GENOMIC PROFILING OF INTRACRANIAL GERM CELL TUMORS
C.C. Lau; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA Intracranial germ cell tumors (GCTs) are relatively rare and heterogeneous brain tumors affecting primarily children and adolescents. Although pure germinomas in general have favorable prognosis, other malignant GCTs such as embryonal carcinoma, yolk sac tumor, and choriocarcinoma have much poorer outcome. The goal of future developments in the management of intracranial GCT is to reduce treatment-related morbidity in germinoma patients and improve survival in those with nongerminomatous GCT. Such therapeutic advancements will depend on our improved understanding of the biology of these tumors. Since the phenotype and clinical behavior of every tumor is determined by the underlying genetic alterations, we hypothesize that the use of comprehensive genomic profi ling to identify these genetic alterations is a systematic and unbiased approach to charac-We studied the gene expression characteristics and genomic abnormalities of frozen MGCTs banked with the UKCCSG to determine whether these heterogenous tumors share fundamental genetic abnormalities and whether distinct profi les associate with particular clinical and/or pathological features. In this study, 38 MGCTs underwent histological confi rmation followed by nucleic acid separation using TRIzol. RNA quality and integrity were determined by spectrophotometry and microelectrophoresis. Standard Affymetrix protocols were followed for the U133A genechip and analyzed by using GeneSpring. Extracted and DOP-PCR-amplifi ed DNA, once labeled, underwent both metaphase and array CGH analysis (at 1-MB intervals) across the entire genome. Of 38 MGCTs analyzed, there were 14 germinomas (3 intracranial), 23 yolk sac tumors (9 within teratomas), and 1 embryonal carcinoma. All yielded suitable DNA, and 32 produced high-quality RNA. Expression analysis demonstrates substantial homology between tumors, and supervised clustering against mature and immature gonad controls reveals "new cancer biomarkers" in this tumor group. Unsupervised clustering divides the tumors by histology, producing "cancer signatures," with as few as 133 genes discriminating between germinomatous and nongerminomatous tumors. Regarding CGH, recurrent gains of 1q, 12p, and 19 were observed in greater than half of the cases, with frequent gains on chromosome 2, 11q, 17, 20, and 21. Loss of 1p, 4, 6q, and 13 was present in a third or more of cases. When compared to the clinical parameters and outcome information from the UKCCSG GC II Protocol, there was no correlation between any particular genetic abnormality and histology, age at presentation, primary site, tumor stage, or survival. Array CGH analysis confi rmed these gains and losses, but also consistent and novel areas of genomic imbalance, with areas which discriminate between histologies. We conclude that while broadly similar (irrespective of whether intracranial or extracranial), the gene expression profi les of pediatric MGCTs differ signifi cantly from controls and cluster independently by histology. A limited number of genes account for these differences and are currently under further investigation. The genomic imbalances present confi rm previous gains and losses on chromosomes 1, 4, 6, 12, 13, and 20, but with chromosomes 17 and 19 in particular meriting further investigation.
*B6. GENETIC ANALYSIS OF CENTRAL NERVOUS SYSTEM GERM CELL TUMORS (CNS-GCT)
D.T. Schneider, S. Zahn, K. Alemazkour, S. Sievers, A.E. Schuster, G. Calaminus, U. Göbel, and E.J. Perlman, on behalf of the Pediatric Oncology Group and the German GCT study group; Clinic of Pediatric Oncology, Hematology and Immunology, Heinrich-Heine-University, Duesseldorf, Germany
The objective of our study was to characterize genetic profi les in CNS-GCT in children and adolescents. After histologic review, fresh-frozen or archival tumor samples from 17 patients (12 male, 5 female, median age of 11 [neonate-25 years] ) were analyzed with comparative genomic hybridization. Among these, there were six germinomas, seven malignant nongerminomatous CNS-GCTs, and four pure teratomas. Tumor DNA and normal male control DNA were differentially fl uorescence-labeled and co-hybridized against normal metaphases. The tumor-to-control ratio of fl uorescence was analyzed with a designed software package (Applied Imaging Inc.). All germinomatous and nongerminomatous CNS-GCT and two of four pure teratomas showed multiple chromosomal imbalances. Chromosomal gains (median, 5; range, 1-9) were observed more frequently than losses (median, 1; range, 0-4) . Among the chromosomal losses, parts of chromosome 11 (n ϭ 5), 18 (n ϭ 3), and Y (n ϭ 2) were deleted most frequently. Chromosomal gains were most commonly found at 12p (n ϭ 10), 1q (n ϭ 7), 8 (n ϭ 8), 3p (n ϭ 4), and the X chromosome (n ϭ 4). In two cases, gain of 12p was sharply confi ned to an amplicon at 12p11, thus delimiting the commonly amplifi ed region on 12p. Notably, we observed no difference in the genetic profi les of germinomatous and nongerminomatous CNS-GCT. At the current state of this ongoing study, we have found no siginifi cant correlation of specifi c genetic imbalances with clinical outcome. We conclude that malignant germinomatous and nongerminomatous CNS-GCTs show similar patterns of chromosomal imbalances. Their genetic profi les correlate with those found in mediastinal and gonadal GCTs in children and adolescents, which are characterized by gain of 12p in malignant GCT of adults. This observation and accompanying epigenetic studies refl ect the common histogenesis of gonadal and nongonadal GCT. This study was supported by a Max-Eder grant of the Deutsche Krebshilfe.
Previous studies demonstrating biallelic expression of the imprinted genes H19 and IGF2 and loss of DNA methylation of the SNRPN gene have indicated a common precursor cell of GCTs, being the primordial germ cell (PGC). We applied the novel MS-SNuPE technique for the analysis of the IGF2/H19 imprinting control region (ICR) in 55 GCTs (22 children, 7 adolescents, 26 adults) from representative clinical and histologic subgroups. Most GCTs showed low levels of methylation at the IGF2/H19 ICR. All eight ovarian GCTs, 9 of 10 testicular seminomas, 7 of 10 testicular nonseminomas (all adolescents/adults), 6 of 9 testicular yolk sac tumors (YSTs), and 12 of 14 nongonadal GCTs (all infants/children) showed hypomethylation. The highest methylation levels were observed in three childhood YSTs and 2 of 4 spermatocytic seminomas, which are derived from advanced stages of spermatogenesis. We conclude that the predominantly low methylation status of most of the other GCTs correlates with studies demonstrating erasure of the methylation imprint of the IGF2/H19 ICR during embryonal PGC migration and early spermatogenesis. These fi ndings indicate that both gonadal and nongonadal GCTs originate from PGCs that have erased their methylation imprint. Furthermore, this study indicates that imprinting control mechanisms other than the proposed CTCF boundary model are regulating IGF2 expression during this stage of germ cell development and derived GCTs. This study was supported by a MaxEder grant of the Deutsche Krebshilfe.
*B8. GENOME-WIDE HIGH-RESOLUTION IDENTIFICATION OF NOVEL GENOMIC ALTERATIONS IN BRAIN TUMORS
H. Yan; Brain Tumor Center, Department of Pathology, Duke University Medical Center, Pediatric Brain Tumor Foundation Institute, Durham, North Carolina, USA Malignant brain tumors are the most devastating cancers. However, the molecular pathogenesis remains poorly understood. A comprehensive molecular profi ling of the tumors will allow increased accuracy of disease risk stratifi cation for patients with brain tumors and will lead to the identifi cation of novel therapeutic targets. Recently, through a combination of novel genetic approaches and biochemical methods, we have identifi ed and characterized several new genetic alterations contributing to the pathogenesis of brain tumors. Whereas comprehensive screens for activating or inactivating mutations would require sequencing and functional studies of tens of thousands of genes, measurements of the genomic DNA copy-number, or gene dosage, within chromosomal segments can be far more amenable for analysis. Complete sequencing of the human genome has made possible the development of novel techniques that narrow the resolving power of genome-wide screens to regions covering one or a small handful of genes (р1 Mb). Through a genome-wide high-resolution screening, we identifi ed multiple genetic alterations of medulloblastomas by digital karyotyping.
OTX2 (human orthodenticle homolog 2) is one of the identifi ed oncogenes of anaplastic medulloblastomas. We found that OTX2 was amplifi ed more than 10-fold in several medulloblastoma cell lines. Normally, OTX2 is expressed during the brain development and turned off in adult brain tissues. Gene expression analyses showed that OTX2 transcripts were present at high levels in 14 of 15 (93%) medulloblastomas with anaplastic histopathologic features. Knock-down of OTX2 expression by siRNAs inhibited medulloblastoma cell growth in vitro, whereas pharmacologic doses of alltrans-retinoic acid repressed OTX2 expression and induced apoptosis only in medulloblastoma cell lines that expressed OTX2. These observations suggest that OTX2 is essential for the pathogenesis of anaplastic medulloblastomas and that these tumors may be amenable to therapy with alltrans-retinoic acid. Recently, we also detected the expression of OTX2 in pineoblastomas. On the basis of various characteristics, including age of the patient at clinical presentation, histology, chromosomal constitution, status of genomic imprinting, and chromosomal constitution, different entities of human germ cell tumors (GCT) can be recognized (Oosterhuis and Looijenga, Nat. Rev. Cancer, 2005) . These are found at specifi c anatomical locations, including hypothalamus/pineal gland regions. The clinical behavior is dependent on a number of parameters, including sex of the patient, age at clinical presentation, and histology of the tumor. Within the brain, two groups of GCT can be distinguished, (1) yolk sac tumors and teratomas and (2) seminomatous tumors (classifi ed as germinoma) and nonseminomas. These entities of GCT have specifi c genomic aberrations, which support existence of different pathogenetic pathways and genes involved. One of the most recent steps forward in the diagnosis of seminomatous-GCT and embryonal carcinoma, being the undifferentiated component of nonseminomas, is identifi cation of OCT3/4 (POU5F1) as a immunohistochemical marker (Looijenga et al., Cancer Res., 2003) . Its value has been demonstrated in multiple independent studies, and it is now generally considered as most informative. This presentation includes an update on the actual status of OCT3/4-POU5F1.
*B9. HUMAN GERM CELL TUMORS: IDENTIFICATION OF RELEVANT SUBGROUPS

*EP1. EPIDEMIOLOGY AND OUTCOME OF CNS GERM CELL TUMORS IN THE UNITED STATES, SEER, 1975-2000, A DISEASE OF ADOLESCENTS AND YOUNG ADULTS (AYA)
A. Bendel, J. Watterson, L. Ries, and A. Bleyer; Children's Hospitals and Clinics, Minnesota, Minneapolis, Minnesota; National Cancer Institute, Bethesda, Maryland; St. Charles Medical Center, Bend, Oregon; Children's Oncology Group, Arcadia, California; USA Data from the NCI Surveillance, Epidemiology and End-Results (SEER) Program were analyzed to determine the incidence and outcome of CNS germ cell tumors in the United States. The SEER incidence and SEER 5-year survival of CNS germ cell tumors were determined for each 5-year age group and 15-year age group from 0 to 44 years of age between the years 1975 to 2000. CNS germ cell tumors were seen almost exclusively in individuals between the ages of 0 and 34, with a peak incidence of 0.2 per 100,000 person-years at ages 15 to 19. Thirty-four percent of CNS germ cell tumor occurred between ages 0 and 14, 57% between 15 and 29, and 9% between 30 and 44. The incidence of CNS germ cell tumors in males, all ages combined, was 3.7 times that seen in females, but in the adolescent and young adult group, the incidence in males was more than 12 times that seen in females. A marked male predominance was seen for pineal region germ cell tumors (male:female of 18:1), but there was no gender predilection for pituitary location. Pineal region tumors outnumbered suprasellar tumors by a ratio of 5.4:1. The 5-year survival rates, in the recent era, for all subtypes of CNS germ cell tumors combined were 81% for ages 0 to 14 and 94% for ages 15 to 29. These survival statistics mainly represent the outcome for germinomas, which comprised 58% of the 0-14-year age group and 82% of the 15-29-year group. A steady improvement in survival for CNS germ cell tumors has been seen over the last two decades in individuals 0-14 years of age and 15-29 years of age. CNS germ cell tumors are predominantly an AYA neoplasm, and thus they are the model tumor type for future international collaborative AYA trials. We propose a multicontinent, combined age approach to the treatment of CNS germ cell tumors, which will allow for randomized trials and further advancement in knowledge of these rare tumors. Epidemiological data on ICGCT are available in cancer registries and clinical case series. Signifi cant discrepancies between registry data and clinical series and clinical series raise the question of the quality and reliability of the information available. We reviewed data from IARC on nine countries (Japan, Singapore, Germany, UK, Denmark, US, Israel, Colombia, Canada), the Brain Tumor Registry of Japan (BTRJ), information collected from 25 series of patients with ICGCT (1132 patients), and publications on teratoma in infants (n ϭ 232). Data were collected on age, gender, histology, tumor site, tumor markers, and outcome. Data from registries confi rm signifi cant variation in the incidence of IGCT, with a higher incidence in Asian countries. ICGCTs account for 0.4% (SEER-US) to 2.4% (Japan-Osaka) of all CNS tumors and 8.1% (Israel) to 41% (Denmark) of all germ cell tumors. During the period 1984 to 1996, the BTRJ recorded 1463 ICGCTs (vs. 591 medulloblastomas), which represent 2.8% of all CNS tumor and 15.3% of all pediatric CNS tumors. SEER data for 1975 to 1995 suggest a steep increase in the incidence of IGCT (0.5 cases/million in 1975 IGCT (0.5 cases/million in -1979 IGCT (0.5 cases/million in to 1.9/million in 1990 IGCT (0.5 cases/million in -1995 . Differences are reported in the male/female ratio ranging from 1.0 (SEER-US) to 3.47 (BTRJ). The M/F ratio is signifi cantly higher in published series (n ϭ 3.6). Information on tumor site, histology, and tumor markers is available only from published series and the BTRJ. Forty-eight percent of IGCTs arise in the pineal area and 30% in the suprasellar region. Some risk factors for ICGCT have been identifi ed, including Klinefelter's syndrome and Down syndrome. The high prevalence in the Asian population seems to persist in transplanted populations. In infants, teratomas account for 5.4% of brain tumors, with large variations between series and no evidence of ethnic specifi city. We conclude that available data on epidemiology of IGCT are limited. Signifi cant benefi t would be achieved in considering national and international registries that systematically collect relevant information on these tumors. CNS GCTs in the fi rst year of life seem to represent distinct clinicopathological entities, but more studies are necessary in order to better clarify their biological, genetic, and clinical peculiarities. All cases with diagnosis of GCTs and age р 1 year, registered by the Italian study for infant CNS tumors, were eligible for the present study. Ten cases were registered, three males and seven females, whose ages ranged from 0 to 1 year (median, 5 months). Tumor types were as follows: mature teratoma (MT), three; immature teratoma (IT), fi ve; gonadoblastoma, one; and yolk sac tumor (YST), one. Sites of involvement were as follows: posterior fossa, two; suprasellar, one; pineal, one; cerebral hemisphere, three; temporal fossa ϩ skull base, one; sphenoidal bone with intracranial extension, one; and spinal, one. All patients presented with negative markers. The three cases with MT are alive at 11, 12 and 14 years from diagnosis; two of them underwent complete surgical removal. Residual tumor after surgery was present in one case; no irradiation was delivered in all three cases; in the case with residual tumor, no progression was observed at last follow-up (14 years after operation).
*EP2. EPIDEMIOLOGY OF INTRACRANIAL GERM CELL TUMOURS (ICGCT)
E
*EP3. INTRACRANIAL GCTS IN THE FIRST YEAR OF LIFE: REPORT ON 10 CASES OBSERVED BY THE INFANTS CNS
In the fi ve cases of IT, three showed only foci of IT in a prevalent mature component; all of them are long-term survivors (mean follow-up of 9 years) without any adjuvant treatment after surgery. Two patients had pure IT containing mainly neuroepithelial tissue; both required chemotherapy (one because no tumor removal was possible; the second because of regrowth after complete removal and a "wait and see" approach). The fi rst case had severe complications during chemotherapy, preventing its completion; this patient died of tumor progression. The patient with gonadoblastoma died soon after diagnosis, as no treatment was feasible (congenital huge tumor); the patient with YST is a long-tem survivor (7 years from diagnosis), having been treated with systemic chemotherapy for one year (carboplatin, cyclophosphamide, vincristine, bleomycin and etoposide) . We conclude that CNS GCTs in the fi rst year of life are mainly teratomas; a consistent proportion of them present with immature components that, when limited to foci within a mature pattern and completely removed, do not require adjuvant treatment.
The Canadian Pediatric Brain Tumor Consortium, a network of all pediatric neuro-oncology programs in Canada, conducted a national survey to determine frequency and characteristics of CNS germ cell tumors in Canada. A national retrospective hospital chart review was done. Inclusion criteria for patients were to be under the age of 18 years with a diagnosis as having a CNS germ cell tumor between 1990 and 2004. Chart review included age and year of diagnosis, pathological diagnosis, ethnic origin, location of tumor, and biological markers. A total of 112 cases were ascertained, which revealed a mean yearly incidence of 0.09 cases per 100,000 person-years. Though incidence of case ascertainment varied from year to year, clear trends were not seen. Incidence of germinomas (N ϭ 72) was 0.67 per 100,000 person-years with a 2.4:1 male prevalence. Mean age of onset was 12 years. Tumor locations were pineal (41.7%), suprasellar (31.9%), bifocal (15.3%), basal ganglia (5.6%), and hemispheric (5.6%). Twenty-fi ve percent had evidence of disseminated disease at diagnosis. The incidence of nongerminoma GCT (N ϭ 40) was 0.37 cases per 100,000 person-years, with a 7:1 male predominance. Mean age was 10.5 years. Tumor locations were pineal (70%), suprasellar (25%), bifocal (2.5%), and basal ganglia (2.5%). Furthermore, 22.5% had evidence of disseminated disease at time of onset. ROHA is a not-for-profi t institution committed (Fundacion Kaleidos) since 2000 to gathering and disseminating epidemiologic data on childhood cancer, working as a registration net all over the country. The main activity of this net is to establish a childhood cancer registry at almost all the institutions where children with cancer are treated in Argentina. The total Argentine population is 36,260,130 (Census 2001) , of which 28% are aged under 15. The Registry collected data from 67 sources, eight populationbased cancer registries, and two cooperative medical groups. This report includes a total of 4435 cancers, among which are 34 CNS germ cell tumors (0.8%) diagnosed between 2000 and 2003 in persons younger than 15 years of age. Primary tumor sites were coded by using the International Classifi cation of Diseases for Oncology, 3rd Edition (ICD-O-3) and grouped by histologic type according to the International Classifi cation of Childhood Cancer (ICCC, 1996) . After an intensive and exhaustive effort, we have registered about 90% of the estimated cases of leukemia and 80% of the remaining tumors; additionally, we have documented the migration patterns of these patients. We present our CNS germinal tumor experience, number of cases, the distribution of cases by age and sex, location, treatment and overall survival. The objective of this study was to estimate the incidence, describe temporal trends in incidence, and estimate survival rates for all primary germ cell tumors of the brain/CNS (GCTs) and for the following subgroups of GCT: malignant GCT, nonmalignant GCT, and malignant pineal GCT. CBTRUS compiled data on all primary GCT diagnosed between 1997 and 2001 from 15 state cancer registries. Age-adjusted rates were standardized to the Year 2000 U.S. standard population. CBTRUS compiled data from six state cancer registries for all primary GCT diagnosed from 1985 to 1999. Multiplicative Poisson regression was used to calculate the average annual percent change (AAPC [95% CI]) in incidence rates over the time period while controlling for age, sex, race, and microscopic confi rmation, and to statistically compare trends over time. Joinpoint regression analysis was utilized to identify sharp changes in incidence over time. Relative survival rates for primary malignant GCT for cases diagnosed between 1973 and 2001 in nine SEER areas were also estimated. The overall incidence rate for GCT was 0.08/100,000 person-years (py) (CBTRUS; N ϭ 361). The rate was highest in children 0 to 19 years and young adults 20 to 34 years (0.18 and 0.10/100,000 py, respectively). Rates were higher in males than in females (0.11 vs. 0.05/100,000 py), and in whites than in blacks (0.09 vs. 0.04/100,000 py). Overall the incidence of primary GCT (N ϭ 140) did not signifi cantly increase over the time period 1985 to 1999 (AAPC ϭ 3.0% [-0.9%, 6 .9%]). However, incidence rate trends varied by sex, with females experiencing a signifi cant increase over the time period (AAPC ϭ 10.7% [2.5%, 19.6%]) compared to no signifi cant change in males (AAPC ϭ 0.8% [-3.6%, 5.2%] ). Among children (ages 0-19), there was a signifi cant positive time trend (AAPC ϭ 5.1% [0.5%, 9.9%]), while among young adults (ages 20-34), there was no signifi cant change in incidence over time (AAPC ϭ -0.4% [-8.6%, 7 .7%]). The one-, fi ve-, and 10-year survival rates following diagnosis of a primary malignant GCT were 88%, 75%, and 70%, respectively (SEER; N ϭ 363). Additional rates by GCT subgroup, age, sex, and race are presented. This analysis adds to the scant literature on trends in incidence of nonmalignant and malignant GCT of the brain/CNS and may facilitate, along with other descriptive epidemiologic studies, the identifi cation and elucidation of risk factors for these tumors. Intracranial germinoma is highly radiosensitive and associated with excellent long-term survival after craniospinal irradiation. Recent studies aim at optimizing the therapeutic ratio and have examined whether primary chemotherapy allows for reducing volume and/or dose of irradiation. We report long-term results of the SFOP-90 prospective study that delivered combined approach with focal radiotherapy (RT). From 1990 to 1999, 60 nondisseminated, uni-bifocal germinomas, histologically proven (49, three with mature teratoma component) or presumed (11), all with HCG Ͻ50 IU/l -␣FP Ͻ12 ng/ml, received four alternating courses of etoposide-carboplatin, etoposide-ifosfamide, followed by 40 Gy to the tumor bed. Five-and eightyear OS and EFS were analyzed according to Kaplan-Meier; pattern of relapse was reviewed with respect to radiation fi elds. Special efforts were made to conduct an evaluation of neuropsychological profi le and academic achievement. Seventeen girls and 43 boys, ages 5 to 24 (median 13), were registered: pineal, 48%; suprasellar/hypophysis, 36%; and bifocal, 11%. Major response to chemotherapy was obtained in all but four patients (removal of residue showed teratoma in three, necrosis in one). At median follow-up, 76 m (range, 7-136), results were as follows: Five-and eight-year OS, 98% Ϯ 3.6; EFS, 83% Ϯ 310; relapse rate, 16.4%; median time, 36.5 m (range, 10-122). Ventricular dissemination was the predominant pattern of relapse (8/10), at margins or out of radiation fi eld. One patient died of a second relapse. Twenty percent of the children/adolescents had a neuropsychological outcome evaluation that showed good preservation. Quality of staging/management constantly improved over years. Updated results and analysis of predictive factors of ventricular dissemination are presented. We conclude that localized germinoma patients treated by the combined approach using focal irradiation achieve good survival rates and neuropsychological outcome. Pattern of relapse shows the ventricular system as the area at risk of dissemination and suggests enlargement of radiation fi eld at prophylactic dose to include the ventricles. Identifi cation of predictive factors of ventricular spread is necessary if focal radiotherapy is considered. Large volume, full-dose radiotherapy (RT) currently used in the curative management of localized CNS germinoma may cause long-term neurocognitive, endocrine, and hearing impairments. Exploratory studies in the United States, Europe, and Japan have used combined chemotherapy (CHT) and RT or CHT alone to decrease RT morbidity. The Beth Israel Germinoma Consortium (BIGC) accrued 38 patients from 1998 to 2004 using a protocol combining CHT with carboplatin, etoposide, cisplatin, and cyclophosphamide followed by reduced dose Ϯ volume RT in complete responders (CRs). The overall CR rate to CHT was 89% (34/38), and 87% (26/30) of the M0 patients (those with localized disease) received reduced volume (involved fi eld rather than whole ventricular) and reduced dose (30 rather than 45 Gy) RT. After a median follow-up of 45 months, all 38 patients are alive, and the PFS is 89%. COG has very recently launched a phase 3 germinoma trial (ACNS0232) comparing standard radiotherapy (Reg A) to CHT followed by the response-based, reduced radiotherapy (Reg B) similar to the BIGC pilot for patients 25 years and under with histologically confi rmed, newly diagnosed primary CNS germinoma (serum and CSF AFP are normal and serum and CSF HCG are both Ͻ50 mIU/ml). The goals of this study include comparing OS and PFS as well as cognitive function and quality of life. Patients will be assigned to localized (M0) or disseminated disease (M ϩ) categories, and all M ϩ patients will receive CSRT. All M0 patients in Reg A will receive whole ventricular RT (24 Gy) with a boost (21 Gy) to the primary tumor, and all M ϩ patients will receive CSRT (24 Gy) with a boost (21 Gy) to measurable disease. M0 patients in Reg B who have a CR to CHT will receive only involved fi eld RT (30 Gy), and M ϩ patients in CR will receive CSRT (21 Gy) with a boost (9 Gy) to measurable disease. The inclusion criteria for M ϩ are as follows: patients with multiple intracranial lesions, leptomeningeal brain or spinal disease, ϩ CSF cytology, endoscopic observation of intraventricular seeding, intraparenchymal primary tumor; patients with pineal region primaries who present with DI; and M0 patients who have a dramatic reduction in the "uninvolved" pineal or infundibulum after chemotherapy. The BIGC pilot will be reported in detail. ACNS0232 plans to accrue 225 patients over fi ve years. The ACNS0232 trial should be able to resolve whether a reduction in dose and volume of RT, facilitated by neoadjuvant CHT, will improve the cognitive performance and quality of life in long-term survivors of CNS germinoma without compromising overall survival. Treatment for CNS germinoma aims to reduce toxicity and maintain effectiveness. We report on a series of patients treated with combined chemotherapy and radiation. Ten patients with germinoma underwent four cycles of carboplatin and etoposide, followed by radiation treatment. Six patients received involved fi eld irradiation only, two whole ventricle, and two craniospinal axis irradiation. Medical records were reviewed to collect data regarding acute hematopoietic toxicity, treatment response, and survival. Patient characteristics were as follows: Age ranged from 8 to 22 years, with a median of 12.8; seven patients had biopsy-positive germinoma, two had mixed germinoma and mature teratoma, one was diagnosed on the basis of radiographic appearance and presence of CSF beta HCG; two patients had gross total tumor resection. Chemotherapy toxicity was as follows: Grade III/IV neutropenia and thrombocytopenia was seen in 70% of evaluable courses and grade III/IV anemia in 25%; 70% of patients required platelet transfusion, and 40% required packed red blood cell transfusion. The average time to recovery from chemotherapy was 23 days. Chemotherapy response was as follows: Of six patients evaluable for chemotherapy response, four had complete or near complete responses, and two had partial responses. One patient who underwent a gross total resection of tumor developed recurrent disease on chemotherapy. Survival is as follows: Nine of 10 patients are alive without disease, with median follow-up of 16 months. We conclude that acute hematopoietic toxicities are frequent but transient on this regimen. Our report supports the use of preirradiation chemotherapy, showing a high response rate allowing for reduction in volume and dose of radiation therapy in a subset of patients while maintaining good survival over a short follow-up time. The SIOP CNS GCT 96 offers for germinoma two treatment options, either combined treatment with four cycles Carbo-PEI followed by focal RT (40 Gy) (option B) or craniospinal RT, 24 Gy, with a tumor boost of 16 Gy (option A) (also to metastastic sites). In case of metastatic disease, combined-therapy patients also receive craniospinal RT. The comparison of the two therapy arms aims to clarify if both treatment options are equivalent in terms of event-free survival (EFS) rate and toxicity. All registered protocol patients with diagnosis until 01/01/2004 regardless of age and dissemination are evaluated. Protocol patients are all patients who receive the complete and correct therapy according to dissemination. In SIOP 96, 170 protocol patients with CNS germinoma are registered: 127 boys and 43 girls, with a median age of 13. Main localization is as follows: pineal region (49%), suprasellar/hypophysis region (28%), bifocal disease (22%), and other (1%). A total of 113 patients receive option A treatment, of whom 13 are metastatic; 57 patients are treated according to option B, of whom 13 are disseminated. Diagnosis is obtained by stereotactic biopsy in 69 patients, open biopsy in 35 patients, and subtotal or total resection in 42 children; one patient is diagnosed through cytology, and for three patients, no information is available. EFS for option A is 0.93 Ϯ 0.03 (follow-up, 2-116 months, median 35 months) and 0.90 Ϯ 0.04 for option B (follow-up, 4-83 months, median 26 months). Eleven events occurred. Under option A, two patients died of complications that are not directly related to therapy, four patients relapsed locally, and three have a different diagnosis at relapse (2 ϫ YST, 1ϫ im. teratoma). Under option B, there were one local relapse (germinoma [G] ), three ventricular (2 ϫ G, 1ϫ choriocarcinoma), and one spinal (G). We conclude that the outcome of patients with germinoma, with either combined treatment or craniospinal RT only, is excellent. Relapses reveal the importance of complete staging and of control of subclinical disease (ventricular). Registered acute or long-term toxicity of both therapy options is under evaluation. In the forthcoming germinoma protocol, all patients with localized germinoma and a complete workup (CSF, serum, imaging) are treated with a combined approach, including ventricular RT. All metastatic patients will receive craniospinal RT. This study is supported in part by Deutsche Krebshilfe.
*EP6. DESCRIPTIVE EPIDEMIOLOGY OF PRIMARY GERM CELL TUMORS OF THE BRAIN AND CENTRAL NERVOUS SYSTEM IN THE UNITED STATES
G3. RESPONSE TO CARBOPLATIN AND ETOPOSIDE WITH
*G4. UPDATE OF PROTOCOL PATIENTS WITH CNS
Germinoma with syncytiotrophoblastic giant cells (STGCs) are considered to behave more aggressively than usual germinoma, but there is a controversy. The clinical behavior of germinoma, which produce human chorionic gonadotropin (HCG), is not well understood yet. To clarify the clinical signifi cance of germinoma with STGC and HCG-producing germinoma, the tumor marker values and their correlation to the clinical course or response to the treatment were analyzed. Patients with germ cell tumor who were registered for the multi-institutional Japanese Pediatric Brain Tumor Study Group were analyzed. There were 131 germinoma and 39 germinoma with STGC or HCG-producing germinomas (here designated as HCG germinoma). The patients were treated according to the study group protocol (Matsutani 1998); briefl y, chemotherapy (ICE regimen [ifos, CDDP, etoposide] ) or CARE regimen (CBDCA, etoposide) was given initially followed by extended local radiotherapy. The number of courses of the chemotherapy and the radiation dose were determined according to the classifi cation of germ cell tumors of the study group. The range of HCG value was 2 to 200 mIU/ml, and the beta-HCG value was 0 to 233 in HCG germinoma (except one extreme case). These values were lower than those of choriocarcinoma (up to 8,492 for HCG and 20,048 for beta HCG, only one of HCG or beta-HCG was elevated in some patients). After induction therapy, the total tumor-free rate for germinoma was 90.1%, whereas it was 84.6% for HCG germinoma. The recurrence rate was 12.4% and 12.8%, respectively. The fi ve-year-survival rate was 98.3% and 100%, respectively. Since there was no signifi cant difference between two groups in terms of clinical course, the intensity of treatment was compared. The mean radiation dose was higher in HCG germinoma (27.8 Gy vs. 36.9 Gy, P Ͻ 0.01), and the number of chemotherapeutic courses was also greater in HCG germinoma (3.1 times vs. 5.3 times, P Ͻ 0.01). However, the mean number of chemotherapeutic courses until tumor disappearance was somewhat smaller in HCG germinoma (1.9 vs. 1.7). Thus HCG germinomas did not show a worse clinical course compared to germinoma with this intensifi ed treatment protocol. Since the number of chemotherapeutic courses until the good tumor response was not different, we are planning to treat with same regimen for germinoma and HCG germinoma in the coming new study protocol. The concept of combined treatment with chemotherapy and focal irradiation in localized intracranial germinoma was part of the SFOP TGM TC90 protocol. Based on this experience, this treatment option was therefore incorporated in the SIOP CNS GCT 96 trial. All registered germinoma patients (diagnosis until 31/12/03) regardless of age, with histologically proven (resection or biopsy), tumor marker negative (AFP Ͻ 25 ng/ml and HCG Ͻ 50 IU/l), uni-or bifocal (only if pineal and suprasellar) nonmetastatic (no tumor cells in CSF and negative spinal MRI) intracranial tumors and protocol therapy were included. The fi ve-year EFS and survival according to Kaplan-Meier are analyzed. In SIOP 96, 31 boys (ages 6-25, median 13) and 13 girls (ages 5-15, median 10) were registered. Main localization was the pineal region (48%), followed by suprasellar/hypophysis region (30%) and bifocal disease (20%), and other (2%). Within fi ve years of follow-up time, events occurred only in fi ve of 44 patients (8, 9, 10, 18, and 22 months after diagnosis). With a median follow-up of 26 months (4-83 months), EFS was 0.87 Ϯ 0.06, and OS was 0.91 Ϯ 0.06. Out of fi ve event patients, two had a local relapse, and two had a ventricular and one a spinal relapse. Relapse diagnoses were obtained clinically (imaging ϩ markers). In one patient with local relapse, histology after relapse treatment showed an additional teratoma component. One patient with ventricular spread showed choriocarcinoma (clinical) (no CSF-diagnostics at primary diagnosis). He died after several relapses. The second patient with ventricular relapse died of complication. The other three relapse patients are in second remission. We conclude that with a combined therapy approach, patients with localized germinoma achieve excellent survival rates. The ventricular area can be defi ned as the area of risk. Over 50% of relapse patients achieve second long-term remission. This study was supported in part by Deutsche Krebshilfe. Simultaneous involvement of the pineal and the neurohypophyseal regions by a germinoma, also called bifocal germinoma, is variously described in the literature, and its incidence ranges from 6% to 26%. The pathophysiology of these bifocal germinoma is unknown, and as a consequence, it is unclear whether these lesions should be treated as metastatic or nonmetastatic tumors. Few series have focused on this particular subgroup. The objective of this study was to review the incidence, the clinical and radiological characteristics, the therapeutic management, and the outcome for patients with bifocal germinoma. We conducted a retrospective chart and radiology review. Our inclusion criteria were as follows: radiological diagnosis of bifocal lesion involving the pineal and the neurohypophyseal region (CT and/or MRI), negative spinal MRI and CSF, negative tumor markers (serum and CSF). Among the 17 CNS patients with germinoma diagnosed and initially treated at our institution between 1990 and 2004, six patients (5 M and 1 F) fulfi lled the inclusion criteria. Median age at diagnosis was 12.8 years (range, 9-15 years). Three patients had an Asian background. Median time for presenting symptom to diagnosis was four months (range, 1-48 months). All patients presented with diabetes insipidus. Four had panhypopituitarism. Five of six patients had sign of increased ICP, three of six had Parinaud's syndrome. All had negative serum tumor marker (␤HCG, ␣FP), two had elevated HCG in the CSF. On CT and/or MRI, four patients had a pineal mass associated with a suprasellar mass, and two had a pineal mass with abnormal enhancement of neurohypophyseal area. Four patients had hydrocephalus. Three patients were treated without biopsy, one based on a neurosurgeon's decision, and the two others had elevated CSF ␤HCG (14 and 3 UI/l). Three patients underwent an endoscopic biopsy of the pineal mass. In one patient, the endoscopic procedure confi rmed the neurohypophyseal involvement suspected on imaging. All patient received chemotherapy (3 to 4 cycles of VP16/carboplatin/ifosfamide or VP16/ cisplatin) followed by focal radiation. Complete remission was achieved after two cycles in four patients and after four cycles in two patients. Focal fi eld of radiation involved the whole ventricular system (2400 cGy), with a boost to the primary sites (1600 cGy) in four patients. Two other patients received only focal radiation to the primary sites (2500 cGy, 3500 cGy). At a median follow-up time of 48.1 months (range, 6-73.4 months), all patients are alive in fi rst complete remission. This experience suggests that bifocal germinoma can be considered as a locoregional disease rather than metastatic entity and that focal radiotherapy in addition to chemotherapy may be suffi cient to provide an excellent outcome. Refi nement of the staging of CNS germinoma with new diagnostic tools will likely increase the awareness of these bifocal lesions.
G7. BIFOCAL INTRACRANIAL
*G8. TREATMENT FOR INTRACRANIAL GERMINOMA: FINAL RESULTS OF JAPANESE STUDY GROUP M. Matsutani; Japanese Pediatric Brain Tumor Study Group, Japan
After histological verifi cation by surgery, two kinds of chemotherapy (3 courses) were delivered prior to irradiation. A total of 228 patients were evaluated. The median follow-up period was 6.3 years. Results were as follows. (1) A total of 123 patients with germinoma were treated by CARE (carboplatin 450 mg/m 2 on day 1, etoposide 150 mg/m 2 on days 1-3), followed by local irradiation (24 Gy). Whole-brain irradiation was applied for widely disseminated tumor in the brain. For large tumors or multiple tumors, an ifosfamide, cisplatin, and etoposide combination, or ICE therapy, was delivered. The total tumor-free rate was 89% after the treatment. Sixteen patients recurred and two patients died. The fi ve-year overall survival rate was 98%. The recurrence rate signifi cantly differed according to radiation volume: 0% by whole-brain irradiation, 28% by limited local fi eld irradiation with less than 2-cm margin, and 6% by extended local fi eld irradiation. (2) A total of 38 patients with HCG-secreting germinomas were treated in the same strategy as the intermediate prognosis group because of their high recurrent rate. In spite of fi ve recurrences, the fi ve-year OSR is 100%. There was no statistical difference in serum HCG or HCB-beta titers between recurrent and nonrecurrent patients. It is concluded that the combination of CARE and 24 Gy of whole ventricular irradiation would be an optimal treatment for pure germinoma. The purpose of this study was to describe the therapy and evaluate the long-term survival in patients treated for CNS germinoma at a single institution. Between 1987 and 2004, 22 patients (16 male) were diagnosed with pathology-proven CNS germinoma. Location of the primary tumor included the suprasellar region (10 patients) and pineal region (12 patients). The median age at diagnosis was 12.9 years (range, 8-16 years), and the last clinical follow-up averaged 6.7 years (range, 1.5-16 years) from initial diagnosis. Primary therapy included craniospinal irradiation (CSI) (n ϭ 22 patients); median neuraxis dose was 2767 cGy (range, 2100-3600 cGy). Eighteen patients had additional radiation therapy boost (CSI/B) to the primary tumor site to a median dose of 4863 cGy (range, 3600-5400 cGy). Six patients received chemotherapy (C) prior to radiation. Initial response to treatment was as follows: one patient with CSI had stable disease (SD), one patient with CSI/B had partial response (PR), six patients with CSI/B had SD, eight patients with CSI/B had no evidence of disease (NED), three patients with CSI ϩ C had NED, two patients with CSI/B ϩ C had SD, one patient with CSI/B ϩ C had NED. At last follow-up, 17 patients had NED, and three had SD. Two patients with NED after initial treatment (CSI/ boost) subsequently died: One patient developed a secondary brain tumor (glioblastoma multiforme) 7.3 years after initial treatment, and the other patient died with cardiac failure of unknown etiology 16 years after initial treatment. The overall survival rate (OS) at fi ve and 10 years was 100% and 86%, respectively. The progression-free survival rate (PFS) at fi ve and 10 years was 96% and 85%, respectively. Death occurred in two patients at a median of 145 months from initial diagnosis (range, 99-192 months) . All male patients have survived. The OS of pineal region germinoma at fi ve and 10 years was 100% versus a fi ve-and 10-year OS of 100% and 75%, respectively, in patients with suprasellar region germinoma. Our data confi rm that CNS germinomas have an excellent prognosis. In our singleinstitution series, factors that favorably infl uence the OS are male gender and pineal location of tumor.
G9. THERAPY AND LONG-TERM SURVIVAL IN PATIENTS WITH CNS GERMINOMA: THE ST. JUDE CHILDREN'S RESEARCH HOSPITAL (SJCRH) EXPERIENCE
G10. THE EARLY APPEARANCE OF GERMINOMA IN THE BASAL GANGLIA
T. Nagasaka, K. Kato, T. Naito, S. Hayashi, T. Okamoto, H. Ikeda, and S. Inao; Department of Neurosurgery, Nagoya First Red Cross Hospital, Nagoya, Japan
Most intracranial germinomas occur in the midline areas such as pineal or suprasellar regions, but sometimes arise in the basal ganglia or thalamus. We report a case of an 11-year-old left-handed boy with a germinoma in the basal ganglia who presented with slowly progressive hemiparesis and mixed aphasia. CT scans demonstrated a subtle high-density area over the basal ganglia and anterior horn of lateral ventricle on the right side and ipsilateral hemiatrophy in the basal ganglia and cerebral cortex. The MR images also showed hemiatrophy of the right basal ganglia and cerebral cortex. The lesion was not enhanced by contrast medium. FDG-PET disclosed glucose hypometabolism in the right hemisphere. Followup MR images 11 months later demonstrated heterogeneously enhanced tumor with multiple cysts in the basal ganglia. The diagnosis of germinoma was established by open biopsy. Combination therapy with carboplatin, etoposide and radiation therapy were carried out, but the patient's neurological defi cits remained unchanged. It is suggested that germinoma in the basal ganglia should be included in the differential diagnosis of a lesion that is associated with cerebral hemiatrophy. In the early stages, the diagnosis of germinoma in the basal ganglia and thalamus is diffi cult because of its rarity and nonspecifi c fi ndings. Since this tumor is highly sensitive to radiotherapy and chemotherapy and is potentially curable, early detection and prompt treatment, before the full-blown neurological defi cits emerge, are desirable. In the 20-year period since the availability of MR imaging, 35 patients with newly diagnosed, pathologically and tumor-marker confi rmed pure germinomas (n ϭ 31) or germinomas with mature/immature teratomas (n ϭ 4) were treated at our institution. Mean age at diagnosis was 13 (range, 7 to 25). Sex ratio was M:F ϭ 26:9. Sites of tumor were as follows: suprasellar (11), pineal (16), basal ganglia (1), and thalamus (2). Five patients had metastasis at diagnosis, all of which were intracranial metastasis. Two patients had malignant CSF cytology at diagnosis. Elevated beta-HCG levels (Ͻ350 g/dl) were documented in the serum (4/30) and CSF (11/33) at diagnosis. Fifteen patients underwent third ventriculostomies and seven patients, ventriculo-peritoneal shunts. Gross total resections were confi rmed at diagnosis in eight patients (25%), partial resections in fi ve patients, and biopsies only in 18. Six patients were treated with irradiation only, one craniospinal and fi ve ventricular fi eld ϩ boost to pre-chemo tumor volume. Four of 35 received chemotherapy only, and 25/35, chemotherapy and irradiation. Nineteen of these patients with combined treatment received low-dose irradiation, and six received full-dose irradiation. Six patients have developed recurrent tumor, between 12 months and 51 months following initial diagnosis. Five of the relapsing patients had been treated with combined chemotherapy and irradiation, all receiving local fi eld irradiation plus chemotherapy. One relapsing patient received irradiation only and died from progressive disease. Two additional patients died, one of renal failure during a chemotherapy-only treatment regimen, and one died of disseminated varicella several years off treatment, also following a chemotherapy-only treatment regimen. The overall survival at a mean of four years from diagnosis is 91%. Of patients treated with RT only initially, fi ve of six survive. Of patients treated with chemotherapy only initially, two of four (50%) survive. Of patients treated with combined irradiation and chemotherapy, 25 of 25 (100%) survive. A combination of reduced-dose ventricular fi eld irradiation and boost plus chemotherapy in patients with pathologically confi rmed germinoma and tumor markers documented that Ͻ350 g/dl produces outstanding survival. Long-term follow-up studies are in progress to assess the impact of treatment upon neuropsychological functioning and quality of life and will be presented.
*G11. TREATMENT OF PRIMARY CNS GERMINOMAS: THE CHILDRENS HOSPITAL LOS ANGELES EXPERIENCE
G12. CLINICAL CHARACTERISTICS OF GERMINOMA IN THE BASAL GANGLIA
R. Nishikawa and M. Matsutani; Department of Neurosurgery, Saitama Medical School, Saitama, Japan Germinoma in the basal ganglia (BG) accounts for 10% of intracranial germinoma. Development of MRI has been projecting new images of the disease. Case reports have shown their association of atrophy of BG with Wallerian degeneration of cerebral peduncle. Here we report detailed clinical characteristics of fi ve cases of germinoma in the BG since 1998. All cases were male, and the median age was 11 years. Initial symptoms were hemiparesis in all fi ve cases and precocious puberty in three. MRI fi ndings were irregular and mixed-intensity BG lesions with minimal Gd enhancement in T1WI and ill-defi ned, high-intensity lesion in T2WI with prominent atrophy down to cerebral peduncle, as has been reported. The four cases in which HCG-beta was measured showed high values. In three cases, serum HCG-beta values were less than 1 ng/ml, but were 400-12,800 pg/ml measured by an ultrasensitive EIA technique (Ͻ30 pg/ml in normal control).
After chemotherapy using CBDCA and VP16 following 50 Gy of irradiation, the high-intensity lesions in T2WI did not disappear but stabilized for 22 to 80 months. Hemiparesis did not improve in any cases. One case recurred after 31 months as a choriocarcinoma. Degeneration of cerebral tissue with minimal Gd enhancement in MRI and secretion of HCG-beta in pg/ml levels would be the characteristic, and maybe early features of germinoma in the BG.
G13. SPONTANEOUS REGRESSION IN INTRACRANIAL GERMINOMA
N. Uemiya, J-I. Adachi, K. Mishima, R. Nishikawa, and M. Matsutani; Department of Neurosurgery, Saitama Medical School, Saitama, Japan
We have treated 35 patients with intracranial germinoma since 1997 and experienced four cases that showed spontaneous regression before surgery. Case 1 is a 24-year-old man who had a one-year history of polyuria, polydipsia, and visual disturbance. MRI demonstrated two tumors measuring 2.5 and 2.0 cm in diameter, in the pineal and neurohypophyseal regions, respectively. His visual function drastically recovered after cerebral angiography (CAG). MRI showed that both tumors decreased in size to half that before surgery. Case 2 is an 18-year-old man who presented with headache and diplopia. His tumors were located in the lateral ventricle, neurohypophysis, and pineal region. First, we made a plan to remove the pineal tumor. Our strategy, however, was changed to remove the lateral ventricle tumor since the pineal tumor signifi cantly regressed after CAG. In Case 3, two tumors in the pineal region and neurohypophysis were detected in a 20-year-old man. MRI showed signifi cant regression of tumors immediately before surgery. In Case 4, a 22-year-old man presented with headache. MRI disclosed tumors in the subcallosal area and pineal region, accompanied with hydrocephalus. Both tumors shrank markedly, and hydrocephalus improved before surgery. It is well known that germinoma has chemosensitive and radiosensitive features. We speculate that the preoperative small dose of radiation, such as CT or CAG, is associated with tumor regression in our series. Thus, to make a fi nal strategy of surgery, MRI immediately before surgery is strongly recommended for the tumor evaluation. Central nervous system germ cell tumors (CNS GCTs) are rare primary CNS tumors that are sensitive to radiation (RT) and to chemotherapy (CT). Primary therapy with cranial and craniospinal axis RT is associated with neurologic and endocrine toxicities. Since these tumors are sensitive to CT, we sought to investigate if the use of neoadjuvant CT in conjunction with lower dose RT would allow for optimal tumor-related outcomes with fewer toxicities. Patients Ͼ3 years of age with newly diagnosed CNS GCTs were eligible. Pathology was centrally reviewed. Serum and cerebrospinal fl uid tumor markers (alpha-feto protein [AFP] and beta-human choriogonadotropin [HCG]) were measured in all but two patients. Patients with germinoma (G) who had elevated AFP were classifi ed as nongerminomas (NG). Therapy was with intravenous cisplatin (20 mg/m 2 ) and VP16 (100 mg/m 2 ) on days 1 to 5, delivered every 28 days for four cycles. Patients were then treated with RT: Patients with G who had a complete response (CR) were treated with 30 Gy, and those with ϽCR received 54 Gy. All NG patients with a CR received a dose of 54 Gy, and those with ϽCR received 59 Gy. All patients who had disseminated disease at entry received craniospinal axis RT, with a dose ranging from 19 to 36 Gy (depending on the pathology and response to CT). Patients who had residual tumor after RT were evaluated for surgery. Neurocognitive and endocrine status was evaluated during follow-up. Thirty-four patients (20 G and 14 NG) were enrolled between 1991 and 2004. The median age was 14 years; median duration of follow-up was 7.3 years and 5.7 years for G and NG, respectively. Among the G patients, CT resulted in CR in 11 (55%), partial response (PR) in three (15%), stable disease (SD) in four (20%), and regression (REGR; decrease in size not meeting criteria for PR) in two (10%). Likewise, in NG patients, fi ve (36%) had CR, seven had (50%) PR, and one (7%) each had SD and REGR. After RT, all G patients achieved a CR, and 12 (86%) of the NG patients had CR, with one each having an unknown response and SD. The latter patient underwent surgery after RT. To date, six (2 G and 4 NG) patients have progressed (median time to progression is 6.5 years for G and 4.1 years for NG). Twenty-nine patients were evaluable for toxicity. Only 10 toxicity events that were of grade 4 severity occurred (mainly hematological and gastrointestinal), with no grade 5 events. All but one patient (who died of metastatic disease) are alive. We conclude that the use of neoadjuvant CT with RT results in a very high rate of response in CNS GCTs. This strategy appears to permit the use of decreased doses of RT with acceptable toxicity and excellent, long-term, tumor-related outcomes. Further evaluation and follow-up will be needed to assess the impact of therapy on cognition and endocrine status.
*G14. PHASE II PRE-IRRADIATION CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM GERM CELL MALIGNANCIES
*HP. PRIMARY CNS GERM CELL TUMORS:
A HISTORICAL PERSPECTIVE D. Jenkin; The Hospital for Sick Children, Toronto, Canada Fifty years ago tumors in the suprasellar and pineal regions were diagnosed on the basis of symptoms and imaging which consisted of skull views and air studies. Tumor resection was uncommon, especially in the pineal region, so that tumor histology was usually unknown. Despite these limitations, a fi ve-year survival rate of 80% could be achieved in children and young adults (р25 years) with high-dose radiation treatment (RT) alone. The relative value of craniospinal RT (CSRT) and local RT was controversial. In older patients the same treatments gave much poorer survival rates, about 35%. Autopsy data and the increasing frequency of a histological diagnosis and analogy with gonadal germ cell tumors (GCT) indicated that the high cure rate in the young was due to the higher frequency of CNS germinomas at this age. Over the last 40 years the development of CT and MRI imaging has allowed for the precise anatomical defi nition of the primary tumor and any metastases. Simultaneously, neurosurgical advances dropped operative mortality to 1% and permitted resection of the primary tumor. A tissue diagnosis became available in most patients. Curative chemotherapy for gonadal GCT was progressively developed over these years and was shown to be effective in CNS GCT. Over the last 15ϩ years the relapse-free survival rate for germinomas treated with RT Ϯ resection alone became 90% to 100%, and this proved to be superior to results with chemotherapy alone. Thus for nonmetastatic germinomas the challenge became the achievement of this result with minimum morbidity by the combination of effective chemotherapy and local low-dose RT. The salvage of relapsed germinoma became practical and allowed the search for minimum treatment to be aggressively pursued. In contrast, the overall cure rate for nongerminomatous (NG) GCT was, in the era of RT alone, about 25%. The spectrum of specifi c tumors within NG GCT has compounded the search for successful treatment. It remains unclear whether there is a need to modify treatment protocols for specifi c tumor histologies. Clearly, chemotherapy has markedly improved overall results with fi ve-year survival rates of about 70% and initial complete response rates of Ͼ70% reported. Local control remains the main challenge. Pilot studies which incorporate initial chemotherapy, high-dose local RT and aggressive resection of residual tumor have shown the most promise. The price for these impressive achievements has been high. With current modalities there can be, at best, only moderate room for further increase in cure rates. Decreased treatment morbidity will be an important end point in new studies. Since CNS GCTs are rare, treatment progress will be slow and will require effective international clinical trials. There remains a need for small innovative pilot studies. In this presentation a brief review of past imaging techniques of germ cell tumors will be made followed by the modern approach to the imaging workup of patients with suspected germ cell tumors. The various imaging characteristics of the different types of germ cell tumors will be discussed with particular reference to advanced imaging techniques. Emphasis will be placed on quantitative methods such as multivoxel proton and phosphorus MR spectroscopy, diffusion and perfusion imaging, diffusion tensor imaging, and FDG-PET imaging. The strengths and weaknesses of the various techniques will be discussed. The current imaging protocols for diagnosis and surveillance imaging will be presented. The purpose of this paper was to characterize the MR spectroscopic and diffusion imaging properties of pure pineal germinoma. The quantitative MR spectral appearance of pineal germinoma with correlation to apparent diffusion coeffi cient (ADC) and fractional anisotropy (FA) measurements has not been published previously. We characterize pediatric pineal germinomas using in vivo short-echo time (TE) single voxel 1H-MR spectroscopy with absolute quantitation and both diffusionweighted and diffusion tensor imaging with quantitative ADC and FA measurement to identify characteristic metabolic and cytological features. Multiplanar brain MR imaging, including diffusion-weighted imaging with ADC map, diffusion tensor imaging (25 direction, b value ϭ 1000) with both ADC and fractional anisotropic mapping and short TE proton MR spectra (1.5 T) in six pediatric patients with pathology-proven intracranial pineal germinoma, was reviewed retrospectively. Short TE spectra acquisition permits detection of N-acetyl aspartate (NAA), choline (Cho), and creatine (Cr), as well as fast-decaying components (glutamate, glutamine, myo-inositol (mI), taurine (Tau), and lipids/macromolecules). Voxels were sized to include as much lesion as possible while minimizing inclusion of adjacent brain. Water signal was used as an internal reference, and peak intensities were corrected for the fraction of necrotic/cystic tissue included in the region of interest (ROI) since most metabolites are intracellular (exception, lactate). Automated quantitative analysis was performed by using commercially available software (LC model) to generate absolute metabolite concentrations that were compared with other pediatric tumors studied in this institute. ADC values were computed from ROIs placed over solid tumor regions within the voxel location used for MRS. Scatter plots were derived comparing ADC to specifi c metabolite concentrations. Diffusion tensor imaging was performed in a subset of patients and analyzed on separate workstation with both ADC and FA maps computed. The MRS pattern of six germinoma patients was similar in many ways to observations in other brain tumors: (1) absent NAA peak and (2) NAA/Cr reduction and Cho/Cr elevation. However, several unexpected features were noted. Creatine concentrations were not different from the concentration observed in other tumors, whereas absolute choline was reduced. Prominent lipids/ macromolecular peaks were consistently observed in all germinomas, whereas in other tumors classes a more heterogenous pattern was observed. Taurine, a metabolite so far only identifi ed in medulloblastoma, was identifi ed in all six tumors. Relatively low homogenous ADC values refl ected the primitive cellular nature of germinoma. No correlation between ADC values and individual metabolite concentrations was detected. The degree of FA change was also homogenous, as demonstrated in a subset of cases. Pineal germinomas demonstrate consistent metabolic profi les with respect to both diffusion-weighted imaging and MRS. Pineal germinomas are characterized by elevated choline, lipid/macromolecular, and taurine peaks with reduced or absent NAA peak. The diffusion-weighted and tensor-imaging properties of pure pineal germinomas are homogenous and reflect the hypercellular nature of the tumor. The signifi cance of these observations needs to be evaluated by comparison with the MRS and diffusion patterns of other nongerminoma germ cell traditionally included in the differential of pineal lesions, which is an ongoing project. The overall intent of this protocol was to treat patients with newly diagnosed primary intracranial germ cell tumors with one of two risk-tailored therapeutic regimens, administering two cycles of chemotherapy beyond the point of achievement of complete radiographic resolution and tumor marker normalization, and to avoid the use of irradiation in such patients.
*IM2. PREOPERATIVE MR CHARACTERIZATION OF PINEAL GERMINOMAS: COMBINED DIFFUSION-WEIGHTED, DIFFUSION TENSOR AND MR SPECTROSCOPIC IMAGING
Between
were enrolled on this study. Patients were stratifi ed between two risk-tailored treatment plans. Regimen A: Low-risk pure germinoma (G-LR) localized nonmetastatic, normal CSF and serum tumor markers. Regimen B: Intermediate risk germinoma (G-IR), with either ␤-HCG positive syncytiotrophoblastic giant cells and/or CSF elevation of ␤-HCG less than 50 mIU/ml, and high-risk (NG-HR) biopsy-proven nongerminomatous germ cell tumor or elevated serum and/or CSF alphafetoprotein, elevated serum ␤-HCG, elevated CSF ␤-HCG greater than 50 mIU/ml, or any type with disseminated disease as determined by MRI and/or CSF cytology. Regimen A patients received in cycles 1, 3, and 5 carboplatin/etoposide and in cycles 2, 4, and 6 cyclophosphamide/etoposide. Regimen B patients received in cycles 1-6 carboplatin/cyclophosphamide/ etoposide. Patients who achieved complete response (CR) after two cycles and four cycles received two more cycles and fi nished the treatment. Those without CR after four cycles were to undergo second look and/or irradiation and/or autologous bone marrow transplantation (only for HR) in order to obtain complete radiological response and tumor marker normalization. Results were as follows: 24% of the patients had G-LR, 36% G-IR, and 36% HR. Seventeen of the 25 patients achieved CR after two courses of treatment (CR2m ϭ 68.0%; 95% CI, 49.7%-86.3%); 18 of the 25 patients achieved CR after four courses of treatment (CR4m ϭ 72.0%; 95% CI, 54.4%-89.6%). Only one patient received irradiation as part of initial therapy, and four patients (16%) received irradiation therapy at time of relapse. With a median follow-up time of 28.6 months (range, 12.5-51.5 months), 22 patients are alive without disease, and 20 patients have not relapsed during their follow-up period. The two-year overall survival and event-free survival rates are 87.7% Ϯ 6.7% and 70.1% Ϯ 9.5%, respectively. The preliminary results obtained in this selected group of patients have showed feasibility and effectiveness with this strategy. Longer follow-up is required to determine eventual durable survival.
*IN2. HIGH-DOSE CHEMOTHERAPY (HDC) WITH AUTOLOGOUS STEM CELL RESCUE (ASCR) IN PATIENTS WITH RECURRENT CNS GERM CELL TUMORS (GCT)
S. Gardner, S. Modak, J. Allen, and J. Finlay; New York University, New York, New York; Memorial Sloan-Kettering Cancer Center, New York, New York; Childrens Hospital Los Angeles, Los Angeles, California; USA Multidrug chemotherapy and irradiation are used alone or in combination for most patients newly diagnosed with CNS GCT. Treatment options are more limited for patients with recurrent CNS GCT. Over the past several years, we have used HDC with ASCR in patients with recurrent CNS GCT. We published our initial results (Modak et al., J. Clin. Oncol. 22:1934 , 2004 ) and now present an update with additional patients. Patients with recurrent germinomatous and nongerminomatous CNS GCT were treated on one of four thiotepa-based regimens. The regimens included (1) thiotepa, 300 mg/m 2 /day (d) and etoposide, 250 mg/m 2 /d for three days; (2) carboplatin dosed by using the Calvert formula with an AUC ϭ 7 (maximum 500 mg/m 2 /d) for three days followed by thiotepa 300 mg/m 2 /d and etoposide 250 mg/m 2 /d for three days; (3) temozolomide 150 to 350 mg/m 2 /d for fi ve days followed by thiotepa 300 mg/m 2 /day and carboplatin dosed by using the Calvert formula with an AUC ϭ 7 (maximum 500 mg/m 2 /d) for three days; (4) two courses of thiotepa, 200 mg/m 2 /d for three days, given four to six weeks apart. The single HDC regimen used was based upon the year of transplant. The sequential high-dose thiotepa regimen was given to patients who had more than minimal residual disease at the time of HDC. Twenty-seven patients with recurrent CNS GCT (germinomas, n ϭ 13; nongerminomatous germ cell tumors, n ϭ 14) were treated between 1986 and 2005. Twenty patients received a single course of high-dose chemotherapy; seven patients received the tandem high-dose thiotepa. Ten patients received adjuvant irradiation following the HDC (craniospinal, n ϭ 8; cranial, n ϭ 1; focal, n ϭ 1). Toxicity primarily consisted of pancytopenia and mucositis. There were no toxic deaths. Ten of 13 patients (77%) with recurrent germinomas are alive without disease at a median of 41 months following HDC. Six of 14 (43%) patients with recurrent nongerminomatous germ cell tumors are alive without disease at a median of 27 months following HDC. We conclude that HDC can be administered safely to patients with recurrent CNS GCT and results in long-term survivors, especially those with recurrent germinoma. /day) with osmotic opening of the blood-brain barrier (BBB) on two consecutive days was reviewed. The treatment course was repeated every four weeks for a total of 12 courses. One of the fi ve had received prior radiation therapy, and none had received prior chemotherapy. All fi ve received subsequent radiation therapy within three to seven months after completion of the chemotherapy. Three had focal therapy, and two received radiotherapy to the whole brain and spine. Four of the fi ve had radiographic evaluable disease prior to therapy. Three cases had complete response and one had partial response. The nonevaluable case has remained without any evidence of disease. Median survival is 10.8 years (range, 4.2-15.5 years). Four of the fi ve remain without evidence of tumor recurrence after the chemotherapy and follow-up radiation therapy. One case disseminated to the lumbar spine after initial treatment with radiation therapy (case 1). Prior radiation therapy had been to brain and cervical and thoracic spine, and the tumor recurrence in the lumbar spine and was confi rmed by a biopsy. Enhanced chemotherapy with blood-brain-barrier disruption (BBBD) was started after the development of lumbar metastases. Five months after the completion of a year of chemotherapy with BBBD, lumbar spine metastases were again noted, and radiation therapy was delivered to the lumbar spine. Follow-up spine MRI continued to show enhancing lesions, so another year of BBBD with enhanced chemotherapy was completed without further recurrence. All of the fi ve currently are alive and well without evidence of disease. Adverse events that occurred during therapy included neutropenia, infection, hearing loss, mild anemia requiring PRBC transfusion (1 episode), and one episode of cardiac dysrhythmia. Ototoxicity for the most part can be avoided by administering sodium thiosulfate. It is concluded that carboplatin-based chemotherapy with enhanced delivery with BBBD is a very effective and durable front line treatment for pineoblastoma. Adverse events are minimal, and ototoxicity has been minimal since the addition of sodium thiosulfate following BBBD. Current results with sodium thiosulfate as an otoprotectant are also discussed. Although germinomas are very radiosensitive/chemosensitive and highly curable, about 10% of patients recur. We studied recurrence cases in our 25 years of experience and tried high-dose chemotherapy for repeatedly recurrent cases. Between 1978 and 2004, we treated 41 cases of germinomas (a median follow-up of 77 months). Seven cases had recurrence. Three of them had been treated with conventional chemotherapy alone, and four other cases received extended local irradiation (24 Gy) plus tumor boost irradiation (21 Gy) with platinum-based chemotherapy. As salvage treatment to recurrent tumors, extended local irradiation was done in the former three cases, which showed complete remission for the long term. The other four cases were treated with second-line chemotherapy (ifosfamide/ carboplatin/etoposide) alone. However, although tentative complete remission was achieved, three of the cases showed repeated recurrence for a short time. Finally, high-dose chemotherapy (high-dose carboplatin and etoposide and melphalan) with peripheral blood stem cell rescue was performed in these three cases. They had no lethal toxicity, and complete remission was continued in all three cases. The signifi cant prognostic factors for germinoma recurrence were conventional chemotherapy alone and limited radiation fi eld. High-dose chemotherapy is recommended as salvage treatment for recurrent tumors.
*IN3. CASE REVIEW OF LONG-TERM SURVIVORS OF MALIGNANT PINEAL TUMORS TREATED WITH BLOOD-BRAIN-BARRIER DISRUPTION ENHANCED DELIVERY OF PLATINUM-BASED CHEMOTHERAPY
IN4. SALVAGE TREATMENT FOR REPEATEDLY RECURRENT GERMINOMAS
*L1. CURRENT APPROACHES IN THE MANAGEMENT OF LEPTOMENINGEAL DISEASES: POTENTIAL APPLICATIONS TO CNS GERM CELL TUMORS
F.M. Balis; National Cancer Institute, Bethesda, Maryland, USA The leptomeninges are a common site of recurrence of CNS germ cell tumors, in part because the blood:CSF barrier limits the penetration of drugs to this site. Potential treatment approaches for leptomeningeal tumor spread include the direct instillation of drugs into the cerebrospinal fl uid (CSF). Intrathecal (IT) administration of drugs, such as methotrexate (MTX), is a form of regional drug delivery that has been successfully used in the treatment and prevention of the meningeal spread of leukemia and lymphoma. Because of the small volume of CSF, MTX concentrations exceeding 100 M can be achieved with a dose of 12 mg, resulting in a substantial pharmacokinetic advantage for this route of administration. Although IT MTX will induce a remission in 80% to 90% of children with acute lymphoblastic leukemia (ALL) that has relapsed in the leptomeninges, few of these patients are cured with IT therapy alone, and remission induction rates are substantially lower for leptomeningeal spread in solid tumors. However, as adjuvant or preventive therapy in children with newly diagnosed ALL, IT MTX alone or in combination with IT cytarabine or cranial radiation signifi cantly reduces the meningeal relapse rate. A major limitation of IT drug administration is nonuniform distribution of drug throughout the subarachnoid space. After intralumbar injection of 6.25 or 12.5 mg/m 2 , peak ventricular CSF MTX concentrations ranged from 0.6 to 22 M, which is substantially lower than the Ͼ100-M peak concentration achieved after an intraventricular dose of 6.25 mg/m 2 . MTX concentration within the CSF after IT administration is dependent on the site and mode of administration, bulk CSF movement and absorption, choroidal drug uptake and clearance, and diffusion or transport of drug across the CSF-brain interface. Surgically implanted ventricular access devices, such as the Ommaya reservoir, were developed to provide a convenient and reliable route of delivering drugs directly into the ventricular CSF. Although there are no large, prospective comparative trials testing the effi cacy of this route of administration, retrospective studies suggest that the use of these devices is more effi cacious and less toxic than the traditional intralumbar route. In addition, intraventricular MTX injection achieves higher and less variable drug concentrations in the ventricular CSF and better distribution of drug throughout the subarachnoid space. The limited number of agents that can be safely administered IT also limits the effectiveness of this treatment approach in solid tumors. The clinical development of new IT agents is a slow process. The new agents currently under development, such as mafosfamide, busulfan, and gemcitabine, have greater clinical activity in solid tumors than MTX and cytarabine, and it is hoped that they will improve the effi cacy of IT drug delivery for the treatment and prevention of leptomeningeal recurrences. Treatment options for leptomeningeal disseminated brain tumors are limited by the lack of effective drugs for intrathecal therapy of nonhematologic malignancies. We report on our experience with intrathecal mafosfamide, a preactivated cyclophosphamide derivative, etoposide, and depot cytarabine. Between May 1994 and April 2005, 38 patients aged 2 to 19 years with various poor-prognosis intracranial tumors received intrathecal mafosfamide (n ϭ 32), etoposide (n ϭ 12), and depot cytarabine (n ϭ 7). Mafosfamide was administered at a dose of 20 mg once or twice weekly until remission was achieved and every two to six weeks thereafter as maintenance therapy for a total of 928 administrations (2-63/patient, maximal cumulative dose 1225 mg). Etoposide was given at a dose of 0.5 mg ϫ 5 d every to 3 to 6 weeks for a total of 127 courses (1-31/patient, maximal cumulative dose 71.5 mg). Depot cytarabine was given at a dose of 50 mg in patients older than 9 years and at a dose of 25 mg in a 22-monthold boy once every two to three weeks until remission was achieved, for a total of 21 applications (1-6/patient, maximal cumulative dose 300 mg). Immediate toxicities such as transient headaches, nausea and vomiting, neck pain, and fatigue occurred with mafosfamide but were manageable with premedication. Etoposide rarely caused any discomfort. Transiently decreased vision and bladder control, fever, fatigue, seizure, and headache were also observed with depot cytarabine. No systemic toxicities and so far no long-term adverse effects attributable to intrathecal therapy as evidenced by MRI or neurologic evaluation were observed with either mafosfamide, etoposide, or depot cytarabine. Intrathecal therapy appears to be best suited to treat tumor cells fl oating in the CSF. Early treatment, appropriate dose, and scheduling of administration are probably crucial. Further research should show whether intrathecal therapy when given at initial treatment may help to reduce the dose of preventive radiotherapy. Endocrine disturbances are frequent in patients with CNS GCT. The interval between the appearance of endocrine symptoms and diagnosis varies extensively. This evaluation aims to describe frequency, time of appearance before diagnosis, and further presentation of endocrine impairment under chemotherapy in germinoma and nongerminoma registered in SIOP CNS GCT 96. All malignant CNS GCTs registered in SIOP CNS GCT 96 until diagnosis 01/01/2004 were analyzed according to kind and frequency of endocrinological disturbances at diagnosis, time point of fi rst appearance, and management problems under chemotherapy. In SIOP 96, 349 males (ages 0-42, median 13) and 128 females (ages 0-22, median 11) with a malignant CNS GCT have been registered (germinoma n ϭ 289, nongerminoma n ϭ 188). Tumor locations are pineal (50%), suprasellar/ hypophysis (30%), pineal ϩ suprasellar (14%), and other (6%). Because of tumor location, 83% of patients with suprasellar involvement and 16% of patients with pineal or other tumor origin presented with one (disturbance of sexual hormones n ϭ 9, growth disturbance n ϭ 8, DI n ϭ 90) or more endocrinological failures (n ϭ 109) at diagnosis. Most patients with only one endocrine symptom at diagnosis develop partial or complete panhypopituitarism during follow-up. Retrospectively, for 96% of patients with endocrine disturbances at diagnosis, this was the fi rst symptom of the tumor and was detectable between 9 days and 10 years (median, 6 months) before diagnosis. A total of 188 patients (87%) presented DI postoperatively. These patients underwent craniospinal irradiation (RT) (germinoma n ϭ 66), two courses of CarboPEI ϩ RT (germinoma n ϭ 35), four courses of PEI ϩ RT (nongerminoma n ϭ 62). Among patients treated with CarboPEI, 15 cases (43%) with problems of water balance or handling of DI are described: two slight (grade 1), six moderate (grade 2), and seven severe (grade 3). For CisPEI (n ϭ 26, 42%), six show slight (grade 1), eight moderate (grade 2), nine severe (grade 3), and three untreatable water imbalance. In the germinoma group with RT alone, four cases, all severe, are described (three at the beginning and one case six months after RT). Endocrine impairment is a major issue in CNS GCTs. Exact diagnosis, along with adapted substitution during lifelong therapy with endocrine follow-up under expert supervision, is mandatory. This study was supported in part by Deutsche Krebshilfe. The objectives of this study were to document the consequences of survivorship and to describe the impact upon quality of life of recurrent, disseminated germ cell cancer on a pediatric oncologist/neuro-oncologist. At 26 years of age, while undertaking my pediatric residency in Birmingham, England, I was diagnosed with testicular seminoma, after a period of six months in which both I and my physicians procrastinated as to possible causes for the slowly enlarging, seemingly paratesticular mass. I underwent an orchiectomy followed by "prophylactic" abdominal irradiation (an enlarged node on lymphangiography was "overlooked" at diagnosis). I was "assured" that my cure rate was greater than 90% and that I didn't need to worry about fertility. Nine months later, after experiencing signifi cant gastro-esophageal discomfort, a barium swallow and chest radiograph demonstrated mediastinal nodal and pulmonary metastases. Serum tumor markers were negative. Lymphangiography was negative below the diaphragm. I underwent mediastinal irradiation, achieving a complete response. However, my physicians at that point were talking only in terms of anecdotal cures. One month following completion of my irradiation, one year to the day after my initial orchiectomy, I underwent surgery for a second tumor (found to be a pure germinoma), which I had palpated on the opposite testicle one week previously. Repeat lymphangiography, tumor markers, and chest radiography were normal. A radiation oncologist recommended oral chlorambucil fi ve days per month for one year and levamisole ("the thinking physician's laetrile") three days per week for two weeks each month following the chlorambucil. After a fi rst year following treatment in which imminent recurrence was anticipated, experiencing transient decline in lung function and a transient episode of irradiation-associated hepatitis, no further recurrences or "major" events developed over the ensuing 28 years. "Minor" events included the "unexpected" fi nding of primary hypothyroidism 12 years after the mediastinal irradiation, documentation of pulmonary function at the lower limits of normal, and, after 28 years, documentation of coronary artery disease. Infertility has been countered by adoption of a daughter, now 19 years old; impotency has been avoided through monthly intramuscular injections of testosterone. Colonoscopy every three years for the last 15 years has been unremarkable. Annual chest radiographs are obtained, required for tuberculin positivity rather than for surveillance for recurrence, and show no abnormalities. Having survived disseminated, recurrent cancer, it has been a defi ning experience in my life, contributing to a pervasive sense of optimism yet realism toward my own life and that of my family and my patients. I have found a degree of empathy with patients that I do not believe would have been possible without my own experience. I have learned how patients often ease the path for their physicians to communicate honestly with them. I have also learned that, sadly, despite such life-defi ning experiences, it is also all too easy to "let slip" such lessons with the passage of time. Infrequent dreams are experienced, in which my cancer returns and I must face the possibility of death once again-not bad dreams, but "reawakening" experiences. Every head or back ache is still considered as a late recurrence (such things are not unknown with germ cell cancer) in need of prompt medical evaluation and exclusion. Despite infertility, hormonal medication dependency, mild pulmonary dysfunction, and coronary artery disease, my life in general and my professional life in particular have been all the richer and productive for this experience. The role of optimism yet realism and open, honest dialogue in confronting metastatic, recurrent germ cell cancer, cannot be underestimated. Long-term sequelae of radiotherapy (RT) in germinoma survivors include neurocognitive and neuroendocrine effects and second tumor (ST). The risk of second malignant neoplasm (SMN) is 5%-12%. In this review, we examine the risk of developing ST in intracranial germinoma patients followed or treated at our institution. Between 1977 and 2002, 27 patients were diagnosed with intracranial germinoma by either radiographic fi ndings and documented treatment response (n ϭ 3) or by biopsy (n ϭ 24). All of the patients were treated with RT, and eight received chemotherapy. Median dose to the primary tumors was 4580 cGy (range, 1440-5040 cGy). The cumulative incidence of ST was calculated from the date of diagnosis to the date of ST, last follow-up, or death by using the Kaplan-Meier method. Patients who did not develop ST were censored at the time of death or date of last follow-up. The median age at diagnosis was 16 (range, 8-35). Median follow-up time was 4.5 years (range, 0.3-22.8 years). Five patients (18%) developed an ST, of which four (15%) were SMNs (testicular tumor, glioblastoma multiforme [GBM] , thoracic mesothelioma with known asbestos exposure, and calvarial osteosarcoma). One patient developed a falcine meningioma. The median time to the development of an ST was 12.5 years (range, 2.0-14.3 years). The cumulative incidence of SMN was 10% at 11 years (95% CI, 0%-25%). There was no signifi cant association of age at diagnosis, gender, radiation dose, or chemotherapy with the development of ST. There were seven total deaths, of which three were related to SMNs (mesothelioma, osteosarcoma, and GBM). Two of the three SMNs were in the radiation portals, as was the meningioma. The patient whose death was related to a mesothelioma had prior asbestos exposure. One death was due to respiratory failure and immunocompromised status due to noncompliance with replacement hormone therapy. One patient died with tumor progression. The cause of the two remaining deaths could not be determined. The relative contributions of RT and inherent patient susceptibility to ST in this population cannot be determined and emphasize the need for longterm surveillance. Current trials of chemotherapy and reduced RT dose and volume offer the prospect of a lower ST risk.
*L2. INTRATHECAL CHEMOTHERAPY FOR NEOPLASTIC MENINGITIS: EXPERIENCE WITH MAFOSFAMIDE, ETOPOSIDE AND DEPOT CYTARABINE IN
*LE1. ENDOCRINE DISTURBANCES AND DIABETES INSIPIDUS (DI) IN PATIENTS WITH MALIGNANT CNS GERM CELL TUMORS: CLINICAL APPEARANCE AND DEVELOPMENT UNDER TREATMENT IN SIOP CNS GCT 96
LE2. GERM CELL CANCER: AN ONCOLOGIST'S PERSONAL PERSPECTIVE
*LE3. RISK OF SECOND TUMORS IN INTRACRANIAL
*LE4. CENTRAL NERVOUS SYSTEM GERM CELL TUMORS: LATE EFFECTS ARISING FROM TREATMENT
S.A. Sands; Columbia University Medical Center, New York, New York, USA Primary CNS germinoma is readily curable with relatively large-volume/ high-dose radiotherapy, but the late effects may alter ultimate neurocognitive functioning and quality of life. Prior studies of other brain tumors have associated radiation therapy with defi cits in the domains of intelligence, attention, memory, and psychomotor processing speed, with risk factors including young age at irradiation and increased irradiation volume and dosage level. Furthermore, cranial irradiation may also lead to diminished height, neuroendocrine dysfunction, and hearing loss. Unfortunately, few germ cell tumor follow-up studies have adequately examined late effects of therapy, and most are notably limited by single assessments of IQ on a small subset of survivors. Consequently, further inquiry is warranted that includes baseline and biannual psychological assessments that extend beyond a singular measure of intelligence and provide data on a range of domains such as attention-concentration, memory, and executive functioning, as well as quality of life, social-emotional, and behavioral functioning. However, obtaining baseline assessments of pediatric brain tumor patients, as well as follow-up testing of survivors, has proven diffi cult in previous studies for a variety of reasons, ranging from a lack of insurance reimbursement, insuffi cient testing personnel, inconsistent referrals, and variable interest on the part of oncologists, parents, and patients. Compliance therefore continues to be a major concern negatively impacting the viability of late effects studies, which directly limits our scientifi c knowledge and thus the ability to design new treatment protocols that attempt to improve overall and event-free survival, as well as long-term patient functioning. Obtaining test data following two to three months after radiation therapy will maximize the number of baseline assessments received, allowing for a signifi cantly larger window of time to capture data on a patient who has completed treatment. Moreover, providing assessments at the conclusion of treatment will yield a timely evaluation in terms of preparation for school reentry and appropriate accommodations when warranted. Additionally, it is important to obtain biannual assessments because neuropsychological changes arise over time, whereby survivors who received cranial irradiation continue to learn but at a lesser rate than that expected for the normal population. Consequently, collaboration between the medical oncology and psychology disciplines is required to ensure maximum compliance to obtain follow-up data on the late effects of treatment on this population to clarify the impact of age at diagnosis, duration of follow-up, gender, location, and radiotherapy parameters upon the late effects arising from the treatment of this readily curable form of brain cancer.
*LE5. ENDOCRINE EFFECTS OF PRIMARY CNS GERM CELL TUMORS AND THEIR TREATMENT S.M. Shalet; Christie Hospital NHS Trust, Manchester, UK
Tumors of germ cell lineage comprise 1% to 2% of intracranial tumors in adults and up to 4% in children. The peak incidence is from the end of the fi rst decade to the end of the second decade of life. Suprasellar germ cell tumors represent less than one third of intracranial germ cell tumors, the most common site being the pineal region. Diabetes insipidus (DI) is almost universal at the time of diagnosis and implies involvement of the fl oor of the third ventricle in the region of the infundibulum. Compression of the visual pathway with signs of optic atrophy or restriction of the visual fi elds is also common at presentation. Somewhat less common presenting signs include anterior, pituitary hormone defi ciencies, short stature in the prepubertal population, and hypogonadism in the older individual. Nongerminomatous germ cell tumors (NGGCT) may secrete hCG in suffi cient amounts to induce pseudo-precocious puberty in boys but not girls. If reviewed from the perspective of the commonest endocrine defi ciency, then of 79 patients presenting to an Endocrine Unit with DI, only 8% were found to have a germinoma over an average follow-up period of 7.6 years, and 52% were considered to have idiopathic DI. Thickening of the pituitary stalk or enlargement of the pituitary gland increased the likelihood that the underlying pathology was a germinoma. Treatment with craniospinal irradiation may profoundly affect growth by inducing growth hormone defi ciency (GHD) and impaired spinal growth. The risk of GHD is related to the dose of irradiation delivered to the hypothalamic-pituitary region; if the dose is suffi cient, then panhypopituitarism may ensue, and it is important to remember that pseudo-precocious puberty of any duration may itself precipitate true central precocious puberty.
*LE6. FERTILITY AFTER TREATMENT FOR A CENTRAL NERVOUS SYSTEM GERM CELL TUMOR
C. Sklar; Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA For individuals who are survivors of CNS GCT, fertility can be affected by both the tumor itself as well as the therapies used to treat the tumor. Impaired fertility can occur following damage to the pituitary gland, damage to the ovaries/testicles or damage to both. If the pituitary gland is damaged, which can be caused by the tumor and/or therapies to treat the tumor (e.g., surgery, brain radiation), fertility can be restored with specialized hormonal treatments so long as the ovaries/testicles are relatively normal. Damage to the ovaries/testicles can occur following certain types of treatments, including radiation therapy to the whole spine and, especially, after treatment with certain chemotherapy drugs. The chemotherapy drugs most commonly associated with reduced fertility are the class of drugs known as alkylating agents, which include cyclophosphamide, ifosfamide, thiotepa, and melphalan. Problems with fertility are more common in males and following the use of higher doses of these drugs. Those at greatest risk for infertility are individuals who have undergone autologous stem cell rescue following treatment with high-dose chemotherapy. Some women who remain fertile following completion of therapy may be at risk of entering menopause at an early age. Spinal radiation in females may predispose to preterm births and miscarriages. Tests for fertility include (1) for females, menstrual history and blood tests and (2) for males, blood tests and a sperm analysis. Treatment options are more limited if the fertility problem is due to direct injury to the ovaries/testicles. Nonetheless, newer assisted reproductive technologies (e.g., intratesticular sperm retrieval followed by in vitro fertilization) offer the possibility of parenthood for some survivors who would have been considered infertile in the past. The aim of this prospective study is to assess how 24-Gy, extended local radiotherapy followed by three cycles of platinum-based chemotherapy improves anterior pituitary functions of the postpubertal patients with neurohypophyseal germinoma. Nine patients (6 males; median 18.2 years of age) were enrolled who received this therapy after biopsy. All achieved a CR during chemotherapy. They were evaluated with dynamic hormonal examination enhanced by hypoglycemia with insulin, LH-RH, and TRH, respectively, before biopsy and one year after this treatment. Serum titers of cortisol, GH, LH, FSH, TSH, and PRL were measured at 0, 30, 60, and 90 min after stimulations. The hormonal impairment was judged according to peak values of cortisol (18Ͻ), GH(10Ͻ), JH(5Ͻ), FSH(5Ͻ), base and peak values of PRL(20Ͼ, 20Ͻ), and delayed peak or prolonged plateau of THS. Median follow-up time was 55 months. All patients have been in full performance status without recurrence. The numbers of normalized patients were two before and two after this treatment (2/2) in ACTH, 2/2 in GH, 1/6 in LH, 2/6 in FSH, 4/8 in PRL, and 2/4 in TSH. The numbers of the patients with post-therapeutic progressive function were only two in TSH and one in ACTH. Clinically, a male recovered from ED, and two females from amenorrhea. We conclude that anterior pituitary functions of the postpubertal patients with neurohypophyseal germinoma can be always preserved and occasionally improved after this treatment.
LE7. VOLUME-REDUCED RADIATION FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY IMPROVES ANTERIOR PITUITARY FUNCTION OF THE POST-PUBERTAL PATIENTS WITH NEUROHYPOPHYSEAL
*LE8. QUALITY OF SURVIVAL (QOS) IN CNS GERMINOMA (CNS-G) VS. CNS NONGERMINOMA (CNS-NGGCTS) TREATED ACCORDING TO MAKEI 86/89
J.A. Wiener, G. Calaminus, C. Teske, S. Weinspach, and U. Göbel; University Hospital, Düsseldorf, Germany
In the past, treatment of malignant CNS germ cell tumors included craniospinal radiotherapy (RT) alone. For CNS-G this was standard treatment. CNS-NGGCTs were treated with a combination of chemotherapy (CT) and RT, which was mainly craniospinal with a higher dosage. Although both diseases are highly malignant tumors, the survival rate for CNS-G is excellent (~90%), whereas the prognosis for CNS-NGGCTs needed to be improved. This study highlights the question of whether the higher treatment burden of the patients with CNS-NGGCTs is refl ected in a more negative QoS. Eighty-fi ve patients (61 CNS-G and 24 CNS-NGGCTs) out of 111 patients in the database of the German MAKEI 86/89 studies participated in the inquiry (at least 5 years after treatment). For this, questionnaires concerning psychosocial reintegration (e.g., education, partner, activity), possible disabilities, and quality of life (QoL) (i.e., PEDQOL, Flechtner) were sent to the hospital in charge of the patients. Patients are distributed according their diagnosis. QoS is investigated by using selfreported disabilities, status of reintegration, and QoL as indicators. Characterstics for patients with CNS-G are as follows: 48 boys and 13 girls; age at diagnosis, 7-31 (mean, 14.1); mean age at inquiry, 19.2. Characterstics of patients with CNS-NGGCTs are as follows: 19 boys and 5 girls; age at diagnosis, Ͻ1-20 (mean, 13.8); mean age at inquiry, 18.5. Resection (subtotal/total) was performed in 50% of all patients. RT was administered in 100% CNS-G (mean, 20 Gy) and in all but one patient with CNS-NGGCT (mean, 43 Gy). In comparing CNS-G and CNS-NGGCTs, CT was given as 23%/88%. The most prevalent disabilities are impaired vision (44%/25%) and gross motor disabilities (30%/54%). Hormone substitution is still necessary in 49%/46% of the patients. Of these patients, 49%/62% have fi nished school education already, and 25%/8% have completed professional training. Only 11%/0% patients have permanent partners, but reported a good social integration (e.g., number of friends, sport club membership). QoL questionnaires reveal a signifi cant difference with regard to physical and cognitive functioning, to the disadvantage of patients with CNSNGGCTs (P Ͻ 0.05). We conclude that survivors of CNS-NGGCTs show a more negative QoS than those of CNS-G. To some extent, this may be due to the self-perception of physical and cognitive impairment. This refl ects the severity of the disease and the more intensive treatment. This study was supported in part by Deutsche Krebshilfe.
*LE9. GARDEN OF EDEN MEETS THE INTERNET: UNDERSTANDING NEW MODES OF COMMUNICATION FOR PATIENTS WITH BRAIN TUMORS IN CHANGING HEALTH CARE SYSTEMS
P.M. Zeltzer; Shilysca Inc., Los Angeles, California, USA The dramatic change in health care delivery from private-practitioner based to health maintenance organizations (HMOs) in the United States has created a vacuum of responsibility for self care which the patient has needed to fi ll. The patient's mode of response to this challenge could be affected by mythical interpretations of good and evil from biblical Genesis. How patients ask for and receive health and medical information has followed a doctor-centric model since prehistory to the 1970s. In 1993 Al Gore opened national health resource information to the world through the Internet. More than 50% of adults and children have become Web surfers. The Internet has changed the professional relationship in unanticipated ways. With the democratization of knowledge, a shift has occurred in the balance of power. But patients are not physicians. Though they can become experts in their own disease, patients often do not understand the context of the information they have gathered. As a practical resolution, the lay cancer community has created a sophisticated model for offering and disseminating updated information for the Web-savvy information seeker (www. virtualtrials.com receives 110,000 hits per month), including funding and directed research funds. In toto this has accelerated a fundamental change in the patient-doctor relationship which could not have been anticipated 10 years ago. This presentation explores the development of these events and provides practical solutions for overcoming challenges that have left physicians unable to satisfy their patient's needs and the patient feeling that his or her needs are not being met. The principles apply not just to brain tumors, but to any catastrophic illness.
*MET1. BRAIN METASTASES FROM GYNECOLOGICAL CANCERS: INTRA-ARTERIAL CHEMOTHERAPY WITH OR WITHOUT BLOOD-BRAIN BARRIER OPENING E.
A. Neuwelt and T.P. Murillo; Departments of Neurology and Neurosurgery, Oregon Health and Science University, Portland, Oregon, USA Infusion of chemotherapy into the carotid and/or vertebral arteries is an effective treatment for different brain malignancies. Presented is a series of fi ve cases of brain metastases (BM) arising from gynecological malignancies treated with multimodal therapy consisting of focal radiation; intra-arterial, platinum-based chemotherapy; and infusion into a carotid and/or vertebral artery with or without blood-brain-barrier (BBB) opening; also, intravenous etoposide phosphate and cyclophosphamide was given. The fi les of fi ve patients with gynecological cancers (one endometrial and four ovarian) with BM were retrospectively reviewed with approval of the Institutional Review Board. The functional performance during the course of treatment and survival period is presented. These patients were treated in a multimodal fashion using intra-arterial chemotherapy with or without BBB opening as the fi rst therapy, continued by focal radiation to residual lesions. Five patients with BM from gynecological cancers were treated with intracarotid and/or intravertebral chemotherapy; three had BBB opening and two did not. Carboplatin was infused intra-arterially into a cerebral vessel; simultaneously, intravenous chemotherapy was administered. Residual lesions were then treated with stereotactic radiation. Two years after starting treatment, the three patients with the highest KPS remained fully functional. The two patients with the lowest KPS died within six months after the diagnosis of BM. The median survival starting from the moment when the primary tumor was diagnosed was 46 months. The median time between the primary diagnosis and the diagnosis of BM was 22 months. The median survival from the diagnosis of BM was 32 months. The complications seen were related to chemotherapy toxicity (hematological). Ototoxicity can be avoided for the most part by delayed administration of sodium thiosulfate. Combined platinum-based regimens are the standard chemotherapy for disseminated gynecological malignancies. This treatment is also effective for BM from these organs when administered into the carotid and/ or vertebral arteries; it can be complemented with stereotactic radiation to focal residual lesions. The survival rates achieved with this multimodal approach are comparable to other treatment options with the advantage of preserving good neurological function. This multimodal treatment to BM should be considered as an adjunct to surgery. Central nervous system metastases represent a not uncommon but difficult management issue in patients with extracranial germ cell tumors. Their presentation varies from being an incidental fi nding on imaging studies at diagnosis or during the course of treatment to the catastrophic clinical consequences of acute raised intracranial pressure and/or cerebral hemorrhage. CNS metastases are an adverse prognostic and predictive factor in patients with germ cell tumors of both testicular and extragonadal origin. Despite this, early aggressive surgical and radiation therapy management of these metastases in combination with systemic chemotherapy can facilitate cure in 30% to 80% of patients. This presentation delineates the demographics, presentation, clinical outcome, and therapeutic management of patients with brain metastases from extracranial germ cell tumors. In SIOP CNS GCT 96 for CNS nongerminoma, treatment is guided by dissemination. Patients with localized disease (including bifocal disease) receive after four courses PEI focal RT with 54 Gy, whereas patients with dissemination (CSF positive, mets on imaging) are treated with craniospinal RT (54 Gy). All registered protocol patients with diagnosis until 01/01/2004 regardless of age and dissemination are evaluated. Protocol patients are all patients who receive the complete and correct treatment according to dissemination. In SIOP 96, 122 protocol patients with CNS nongerminoma are registered: 98 boys (ages 4-28; median, 12) and 24 girls (ages 7-20; median, 11). Main localizations are pineal region (55%), suprasellar/hypophysis region (30%), bifocal disease (8%), and other (7%). Diagnosis is obtained by markers ϩ imaging (43%), with biopsy (28%), and with resection (26%). Ninety-six patients without dissemination receive chemo ϩ focal RT, and 26 patients with metastases are treated with craniospinal RT. EFS for nonmetastatic disease is 0.68 Ϯ 0.06 (follow-up time, 2-100 months; median, 25 months) and 0.72 Ϯ 0.10 for metastatic disease (follow-up time, 1-94 months; median, 33 months). Thirty-one events occurred, 25 in patients with focal RT (10 local, 7 [local ϩ] ventricular, 1 spinal, 5 combined, 1 DOD, 1 DOC) and six in patients with craniospinal RT (2 local, 1 [local ϩ] ventricular, 1 [cranial ϩ] spinal, 1 abdominal, 1 DOC). OS is, respectively, 0.77 Ϯ 0.06 (focal RT) and 0.68 Ϯ 0.11 (craniospinal RT). In CNS nongerminoma, chemo ϩ focal RT (у50 Gy) is able to control subclinical disease. Metastatic patients achieve comparable survival rates with chemo ϩ craniospinal RT (equivalent RT-dosage to tumor). Survival is less favorable than in germinoma patients. Relapses are curable only in 20%. In the forthcoming protocol, treatment will be guided additionally by AFP level at diagnosis and residual disease after chemo (which are reported separately) to further decrease relapse risk. This study was supported in part by Deutsche Krebshilfe. Markers (AFP/HCG) are important for a clinical diagnosis in GCT. In SIOP CNS GCT 96, elevation of AFP Ͼ 25 ng/ml and ␤-HCG Ͼ 50 IU/liter in serum/CSF, together with a typical imaging, suggests a clinical diagnosis. The implications of differences in AFP/␤-HCG levels between serum and CSF and the impact of site/dissemination on marker elevation are unclear. In 109 of 196 patients enrolled in SIOP CNS GCT 96, both markers have been measured in serum and CSF. All other patients were excluded. AFP elevation was detected in 61 patients, and the only marker in 33, and ␤-HCG elevation was seen in 71 patients, as the only marker in 43 cases. Of the 61 patients with AFP elevation in serum/CSF, eight patients showed higher AFP levels in CSF than in serum. Eight had disseminated disease but no higher CSF than serum values. Of 71 patients, 17 with ␤-HCG in serum/CSF presented with metastases. Fifty patients showed higher CSF than serum values, and 12 were metastatic. Interestingly, 24/50 had only an increase of HCG in CSF according to the defi ned limit of 50 IU/liter, but 8/24 showed no elevation (Ͼ5 IU/liter) in serum. In pineal cases, 42 patients presented with raised AFP, seven with higher CSF levels. Thirty-three patients had raised HCG, 23 with higher CSF levels. In suprasellar cases, 13 patients showed AFP elevation, higher in CSF in one. Twenty-four patients present with raised HCG, higher in CSF in 16 (chi-squared test not signifi cant). AFP-secreting tumors occur predominantly in the pineal region. Measurement of markers in CSF and serum is mandatory to detect patients with marker elevation in CSF alone. There is no correlation between level of tumor markers in serum or CSF and dissemination or tumor site. This study was supported in part by Deutsche Krebshilfe.
*MET2. BRAIN METASTASES FROM SYSTEMIC GERM
*NG1. UPDATE OF PROTOCOL PATIENTS WITH CNS
*NG2. MARKERS IN SERUM/CEREBROSPINAL FLUID (CSF) IN NONGERMINOMATOUS CNS GERM CELL TUMORS (GCT): IMPLICATION OF SITE AND DISSEMINATION
*NG3. A PHASE II STUDY TO ASSESS THE ABILITY OF NEOADJUVANT CHEMOTHERAPY Ϯ SECOND-LOOK SURGERY TO ELIMINATE ALL MEASURABLE DISEASE PRIOR TO RADIOTHERAPY FOR NGGCT, CHILDREN'S ONCOLOGY GROUP STUDY ACNS0122
S. Goldman, E. Bouffet, P. Chuba, T. Zhou, and I. Pollack; The Children's Oncology Group, Children's Memorial Hospital, Chicago, Illinois; and Children's Oncology Group, Arcadia, California; USA This protocol is aimed at improving progression-free survival and overall survival of intracranial NGGCT, initially by achieving an increased CR/PR rate to a three-drug neoadjuvant chemotherapy regimen (carboplatin, VP-16, alternating with ifosfamide, VP-16) followed by CSI with involved-fi eld boost radiation. For those patients not obtaining CR/PR after neoadjuvant chemotherapy (defi ned by neuroimaging and tumor marker response), second-look surgery will be performed. For those patients with persistent positive markers, residual malignant elements as assessed histologically, or residual unresectable disease, an attempt to increase survival will be made by using myeloablative chemotherapy (thiotepa/VP-16) with PBSC, prior to CSI. The objectives or this study are (1) to observe response rate following three cycles of neoadjuvant chemotherapy (carbo/VP-16 alternating with ifosfamide/VP-16), (2) to evaluate progression-free survival (PFS) and overall survival (OS) following this regimen, (3) to monitor serum and CSF tumor markers (alpha-fetoprotein, beta-HCG) after each cycle of this regimen, and to correlate marker response with radiographic and clinical measures of response, as well as fi ndings at second-look surgery in patients with radiological evidence of residual disease, and (4) to determine whether additional complete responses can be achieved following high-dose chemotherapy (thiotepa and VP-16) with peripheral stem cell rescue in patients with persistently positive markers, histological evidence of residual malignant elements, or unresectable residual tumors following initial neoadjuvant chemotherapy. As of May 1, 2005, 26 patients have been enrolled, and no unexpected GR IV toxicities have been noted. We plan to enroll 80 to 100 children over a projected 42-month period. Accrual is on target.
*NG4. OVERVIEW AND CRITIQUE OF CLINICAL TRIALS IN CNS NONGERMINOMATOUS GERM CELL TUMORS: BALANCING SURVIVAL AGAINST ACUTE TOXICITIES AND LATE EFFECTS OF TREATMENT
S.J. Kellie; Department of Oncology, Children's Hospital at Westmead, Westmead, and the University of Sydney, Sydney; Australia This paper explores the diffi culties in defi ning and refi ning optimal treatment approaches for children and teenagers with germ cell tumors (GCTs) of the central nervous system. Primary GCTs of the CNS are rare, comprising less than 2% of intracranial malignancies before the age of 20. CNS GCTs comprise germinomas and nongerminomatous (secreting) germ cell tumors (NGGCTs). Included in this latter group are endodermal sinus tumor, embryonal carcinoma (yolk sac tumor), choriocarcinoma, mature or immature teratomas with malignant elements, or "mixed" tumors, which comprise both germinomas and elements of both NGGCTs in varying proportions. Patients with GCTs, particularly tumors arising in the suprasellar area, are more likely to have neuroendocrine disorders such as diabetes insipidus, hypothyroidism, growth failure, or hypogonadism. In addition, these patients appear to be at increased risk of neuropsychological defi cits. Pediatric experience with neuraxis irradiation indicates a variable but commonly signifi cant degree of intellectual dysfunction in long-term survivors.
Thus, the treatment of these midline tumors poses a serious dilemma for children because of the risk of potentially serious long-term sequelae in survivors. The fi rst study of the International CNS Germ Cell Tumor Study Group treated patients with carboplatin, etoposide, and bleomycin with or without additional cyclophosphamide. The goal of the study was to assess outcomes in patients treated without radiation therapy. Fifty percent of all patients were treated successfully with chemotherapy only (Balmaceda et al., J. Clin. Oncol. 14:2908 , 1996 . The second international study intensifi ed therapy using cisplatin and cyclophosphamide in all patients; with a median follow-up of 6.3 years, 14 of 20 patients with secreting nongerminomatous GCTs were alive without disease, including eight without relapse or progression (Kellie et al., J. Clin. Oncol. 22:846, 2004 ). The fi ve-year overall survival and event-free survival were 0.75 and 0.45, respectively. The Children's Oncology Group initiated a Phase II study in January 2004 to assess the ability of neoadjuvant chemotherapy Ϯ second-look surgery to eliminate measurable disease prior to radiation using carboplatin, etoposide, and ifosfamide. All patients will receive craniospinal irradiation and also a boost to the involved fi eld. Large, cooperative clinical trials are necessary to defi ne the optimal therapy for patients with nongerminomatous GCTs. Gains in overall survival must be measured against quality of life and neuropsychologic and neuroendocrine outcomes. The prospective identifi cation of biologic or molecular markers may aid the identifi cation of patients for whom less intensive or more intensive therapy is required. It is likely these challenges will take another decade or longer to resolve. In this report of a chemoradiotherapy strategy, defi nition of CNS-SGCT followed SIOP guidelines. From June 1988 to June 2004, 16 patients were accrued to a treatment that consisted of PEB (4 pre-/2 post-RT courses) ϩ CSI (24 Gy/30 Gy if CR/PR after PEB) ϩ tumor boost, that is, focal RT until 1994, thereafter whole-ventricle RT (45 Gy). The M/F ratio was 6.5, and the median age was 13. Eleven of the 16 patients presented with endocrine symptoms lasting two months to six years, 10 of 11 had diabetes insipidus; nine of 15 had hydrocephalus; four presented with metastatic deposits, three with positive CSF, one pulmonary; nine had multiple intracranial locations. Eleven patients underwent surgery, for hydrocephalus shunt in seven (2 ϩ tumor biopsy, 1 ϩ subtotal, 1 ϩ total removal), two had total/ subtotal removal, and two had biopsy. Alpha-fetoprotein (AFP) was pathologic in serum/CSF in 10, ␤HCG in 14. AFP highest values were Ͻ100 in four, Ͻ500 in four, and Ͼ1000 in two. ␤HCG highest values were Ͻ100 in three, Ͻ500 in six, Ͻ1000 in three, and Ͼ1000 in two. Seventy-fi ve percent of patients responded to PEB (CR ϩ PR); the patient with lung involvement rapidly progressed and died. One, who had marker normalization after two cycles of PEB, was submitted to residual teratoma excision. One with CSF seeding received CSI ϩ 4 PEB courses, and one girl received focal radiotherapy only. Fifteen of 16 patients had marker decrease after PEB: 11/15 normalization; all CR after RT. Two patients relapsed at 7 and 11 months with dissemination; the girl locally irradiated relapsed at 92 months (ventricular); one died of pneumonia elsewhere before RT. Three of four patients who progressed/relapsed had markers over 1000. A fourth with AFP Ͼ 1000 UI/liter in serum and CSF therefore received intensifi cation pre-RT and two myeloablative courses after RT obtaining CCR at 24 months. At a median follow-up of 93 months, 5-year EFS/OS was 75%, 10-year EFS and OS were 62.5% and 75%, respectively. Of the 12 survivors, six have a professional activity, three are students, and three are unemployed. This treatment strategy was effi cacious with a good outcome quality. High-risk patients according to markers, more than according to stage, need treatment intensifi cation. Nongerminomas were divided into two groups, the intermediate prognosis group (malignant teratoma and mixed tumors mainly composed of germinoma or teratoma) and the poor prognosis group (choriocarcinoma, yolk sac tumor, embryonal carcinoma, and their mixed tumors). Patients in the intermediate prognosis group were treated by CARE (carboplatin 450 mg/m 2 on day 1, etoposide 150 mg/m 2 on days 1-3) followed by local irradiation (50 Gy). They received additional chemotherapy fi ve times. Patients in the poor prognosis group were treated by ICE (IFOS 900 mg/m 2 , cisplatin 20 mg/m 2 , and etoposide 60 mg/m 2 on days 1-5) followed by whole neuroaxis irradiation. They received additional chemotherapy fi ve times. Results were as follows. (1) The total tumor-free rate after the initial treatment in 40 patients in the intermediate prognosis group was 52%. Eight patients recurred and four of them died. The fi ve-year overall survival rate was 97%. The recurrence rate was signifi cantly different between diseasefree patients and those with residual tumors after the initial treatment. (2) In 27 patients in the poor prognosis group, six patients recurred and died. The three-year overall survival rate was 56%, and patients without recurrence are living, with a median follow-up period of 5.4 years. Throughout the whole study, we have not encountered any serious complications. The interim analysis of 126 patients with NGGCTs registered on SIOP CNS GCT 96 between 1996 and 01/01/2002 identifi ed AFP Ͼ 1000 ng/ml at diagnosis and residual disease after the end of therapy as adverse prognostic indicators. We therefore studied all protocol patients registered since this analysis (up to 01/01/2004) to see if these fi ndings were upheld. All patients diagnosed and registered between 01/01/2002 and 01/01/2004, regardless of age and stage, were analyzed according to initial AFP level and the presence of residual disease and its surgical management after chemotherapy (CT) and at the end of treatment (following radiotherapy, RT). In SIOP 96, 21 boys (ages 7-21; median, 12) and 13 girls (ages 1-17; median, 9) were included in this cohort. The primary site was the pineal in 47%, suprasellar/hypophyseal region in 26%, bifocal in 15%, and other sites in 12%. Six of 34 had metastatic disease and were treated with craniospinal RT after CT. The remainder had focal RT. AFP was Ͻ1000 ng/ml in 29 patients (3 relapses) and Ͼ1000 ng/ml in fi ve (2 relapses) (Fisher's exact P ϭ 0.08). Complete response after treatment was achieved in 19 cases, and of these, seven underwent resection for residual after CT (no relapses). Residual disease was found in nine patients after RT, none of whom had further surgery (5 relapses) (Fisher's exact P Ͻ 0.01). In six patients, no response data were available. Of 23 patients with AFP Ͻ1000 ng/ml at diagnosis and response data, six had residual disease after treatment (3 relapses), compared to three with AFP Ͼ1000 ng/ml (2 relapses). Two patients who relapsed died of disease, and three are still on treatment. The risk of relapse for patients with AFP Ͼ1000 ng/ml is about 40%, for all those with residual disease around 50%, and in the presence of both risk factors, more than 60%. These results suggest the need for treatment intensifi cation in patients with these risk factors in order to improve their chances of survival. This study was supported in part by Deutsche Krebshilfe. In the fi rst SFOP TC-90 protocol (1990 TC-90 protocol ( -1992 , based on 12 alternating courses of carboplatin-VP16 and ifosfamide-VP16 during one year, and focal radiotherapy (RTX) only in case of residue, four of four patients who received RTX are in fi rst CR, compared to only one of 13 patients treated with chemotherapy (CT) only, although six of 13 were cured after relapse. In the TC-92 protocol (1992 TC-92 protocol ( -1999 , 38 patients (median age, 12.5 years) were treated with six to eight courses of the same CT, resection of a residue and focal 50-55 Gy RT (craniospinal for metastatic patients [M ϩ]). Tumors were pineal in 23 patients, suprasellar in 11, bifocal in two, and in other sites in two, and fi ve were M ϩ; 19 secreted ␣FP; 12, HCG; six, both. One embryonal carcinoma was not secreting. One patient who had postsurgical complications died early. One M ϩ patient never achieved CR. The other patients achieved biological CR, two of them with additional cis-platinum, but two had marker reelevation at the beginning of RT. Fourteen patients had a surgical removal of a residue. RT deviations were as follows: 40 Gy in one patient and focal RT in two M ϩ. Eleven patients relapsed: the three patients irradiated with elevated markers, the two M ϩ patients irradiated focally, one with late CR, and fi ve others, eight to 73 months after diagnosis; five patients were salvaged. Two nonrelapsed patients developed AML at seven and 31 months, and one died, and another patient died in CR late after treatment in bad neurological condition. With a median follow-up longer than fi ve years, fi ve-year survival is 73% (range, 57%-85%) and EFS 60% (range, 43%-74%). Among the four patients with AFP Ͼ1000 ng/ml, one M ϩ and one with marker elevation before RTX died; two are alive in CR1. A higher survival rate was achieved with the combined approach, as compared to the previous series treated with CT only. RT should be performed only in patients in biological remission. Relapses could be salvaged. CNS nongerminoma germ cell tumors (NGGCT) are more refractory to therapy than their germinoma counterparts, but treatment with both radiation therapy and chemotherapy has produced a better outcome than either modality alone. From our earlier pilot study, patients who achieved diseasefree status prior to RT, either by surgery or chemotherapy, had the most favorable prognosis. A sequel study was conducted, with the goal of further improving outcome by increasing the CR rate prior to RT by intensifying CHT and second-look surgery, where feasible. Following surgical or tumor marker diagnosis of NGGCT and complete neuroaxis staging, patients were initially treated with four cycles of multiagent CHT 1 . In patients not achieving CR, a second-look surgery was encouraged, followed by tandem cycles of submyeloablative high-dose CHT 2 with PBSC support. Eligible patients had a CNS NGGCT confi rmed histologically, or by elevated serum/CSF markers for AFP or ␤-HCG (Ͼ100 IU/dl). Patients received neoadjuvant 1 : 12 CR -9/27 (2 confi rmed CR at second-look surgery and 3 probable CR with min residual, unconfi rmed surgically); CR rendered by initial surgery, 4/27; partial response (PR) to CHT 1 , 10/27; progressive disease (PD), 1/27. Of the 10 patients with PR to initial CHT, four underwent second-look surgery, of whom two were rendered surgically CR, and fi ve patients received CHT 2 , converting three to a CR. In total, 21/27 patients were rendered CR prior to receiving RT (12 with CHT 1 , 3 with CHT 2 , and 6 with surgery). There was a trend toward better three-year PFS in the 15 patients who achieved CR before RT (71%) as compared with the six patients who did not (50%). At a median follow-up of 59 months, 18/27 patients (66%) are without disease progression (17 NED and 1 toxic death without progression), and 20/27 patients (74%) remain alive. Nine of 27 patients experienced a relapse, which was outside the RT fi eld in three of six patients who had disease progression after RT. The median TTP was 9 months (4-54 months). This pilot study achieved a higher CR rate prior to RT than our earlier study (78% vs. 61%), with an encouraging 66% fi ve-year PFS. The attainment of a CR prior to RT may have contributed to improved progression-free survival. The pattern of relapse outside the radiation fi eld in three of six patients who progressed after RT emphasizes the need for craniospinal RT volume in these patients. Intracranial teratoma (TER) is a specifi c entity of CNS GCTs defi ned as "benign" disease. Complete resection is the treatment of choice but not always feasible because of the tumor volume at diagnosis and its involvement with critical structures. No standardized treatment exists in incompletely resected or recurrent TERs. We analyzed the outcome of an unselected group of teratoma patients registered on the SIOP CNS GCT 96 study.
*NG5. CENTRAL NERVOUS SYSTEM SECRETING GERM CELL TUMORS (CNS-SGCT): A SINGLE INSTITUTIONAL EXPERIENCE WITH LONG FOLLOW-UP
*NG7. UPDATE ON PROTOCOL PATIENTS WITH MALIGNANT NONGERMINOMATOUS CNS GERM CELL TUMOURS (NGGCT) TREATED ACCORDING TO SIOP CNS
*NG8. REVIEW OF THE SFOP TGM-TC 90 AND 92 PROTOCOLS FOR PATIENTS WITH INTRACRANIAL SECRETING GERM CELL TUMORS (SGCT)
All registered patients with the diagnosis of a primary CNS TER until 31/12/2003 were analyzed, along with outcome in relation to age, tumor size, grade of immaturity, surgical intervention, and additional treatments. Twenty-one boys (ages 0-19; median, 6) and fi ve girls (ages 0-8; median 0) with TER were identifi ed. The primary tumor localization was pineal in 54%, suprasellar/hypophyseal in 19%, and other (mainly newborns) in 27% of cases. Median tumor size was 5 cm (range, 1.2-8 cm). In two cases, no surgery was performed because of tumor size. Median follow-up is 29 months (range, 2-108). One newborn received palliative care only and died, and a second (age 3 years) failed to respond to one cycle of carboPEI and died. In six patients a biopsy/partial resection, in three patients a subtotal resection, and in 15 patients a total resection was achieved at the fi rst surgical intervention. Histology confi rmed an immaturity grade 0 (mature) in 11 patients, grade 1 in three patients, grade 2 in fi ve patients, and grade 3 in four patients. In addition, one patient with a mixed TER grade 1 contained elements of a rhabdomyosarcoma. Only one patient in the group of grade 0/1 TERs (n ϭ 14) received postoperative additional therapy (24 Gy craniospinal radiotherapy). In this group, fi ve events occurred (all alive). Seven of 10 patients with grade 2/3 TERs received adjuvant chemotherapy and additional irradiation (n ϭ 4). In this group, three events occurred (all dead). Only one patient of the whole cohort recurred with a mixed malignant tumor and died subsequently. Event-free survival of the whole group (n ϭ 26) was 53% Ϯ 13%, and overall survival was 79% Ϯ 9% at fi ve years. We conclude that tumor size in infants tends to be larger and less operable than that in older patients. Adjuvant treatment was usually offered only to patients with immature TER. The impact of resection and/or adjuvant treatment for outcome remains unclear. A standardized treatment recommendation is needed to defi ne optimal treatment strategies in the future. This study was supported in part by Deutsche Krebshilfe. We reviewed our experience with CNS teratoma retrospectively to evaluate the role of surgery for these tumors. Between 1980 and 2004, fi ve patients with CNS immature teratoma and two patients with immature teratoma mixed with germinoma were treated at Kyoto University Hospital. They were all histologically verifi ed. Serum titers of AFP and/or HCG were elevated in all cases. Five patients underwent total removal of the tumor followed by radiation therapy with or without chemotherapy, and all of them were almost fully active in their daily life. In another case with pineal immature teratoma, the patient suffered severe morbidity because of intratumoral hemorrhage from partially resected tumor. The other was the most recent case in which suprasellar residual immature teratoma showed malignant transformation with sarcomatous component after a four-year stable period. In our cases with CNS immature teratoma, a high extent of removal of the tumor followed by adequate adjuvant therapy generally conferred a favorable outcome. In the management of the residual tumor occurring after initial therapy, our experience supports the importance of the second-look surgery; otherwise, it is necessary to observe the residual tumor cautiously because of its malignant potential. 3 Department of Neurosurgery, Saitama Medical College, Saitama; Japan CNS pure germinomas (PGs) produce and secrete minimum tumor markers. Although recent advances in sensitive immunohistochemistry have suggested possible production by PG of HCG-beta, lack of sensitivity of current IRMAs has so far failed to consistently detect HCG-beta in the peripheral blood (PB) or cerebrospinal fl uid (CSF) of most patients with PG. In previous studies, we developed a novel and ultrasensitive EIA (immune complex transfer-EIA, ICT-EIA) for HCG-beta, which was 1000 times more sensitive (LD, 0.03 pg/ml) than conventional IRMAs (LDV, 100.0 pg/ ml) with high specifi city (cross-reactivity with LH Ͻ 0.02%). All samples obtained from patients with germinomas as well as healthy controls showed detectable levels of HCG-beta (Ͼ2.0 pg/ml). High levels of HCG-beta in the CSF of PG, with an increased CSF/PB ratio (Ͼ2.0), suggested possible production of HCG-beta by tumors; those were immunohistologically negative for HCG-beta. In the present study, we examined gene expression (real-time PCR, ABI 7000) and production of HCG-beta (ICT-EIA) in histologically verifi ed specimens from PG (n ϭ 4), meningioma (n ϭ 5), teratoma (n ϭ 3), and germinoma with STGC (n ϭ 1). Both gene expression and tissue content were high in PG, whereas meningiomas and teratomas showed minimum HCG-beta gene expression and content. Samples from germinoma with STGC and placenta showed highest gene expression and tissue contents of HCG-beta. HCG-beta levels in both PB and CSF of patients with CNS degenerative diseases or non-germ cell tumors of young adults were 5 to 30 pg/ml, with a CSF/PB ratio of less than 1.5, whereas untreated PG showed high levels of 47.5 to 173.0 pg/ml, with a CSF/PB ratio of 2.0 to 10.0. When patients were successfully treated, both the size of the tumor and HCG-beta levels in CSF and PB fell to Ͻ30 pg/ml, with decreased CSF/PB ratios (around 1.0). These results suggest (1) that PGs produce and secrete HCG-beta into the CSF and (2) that HCG-beta in the CSF as assessed by the ICT-EIA could be a useful tumor marker in patients with PG. Germ cell tumors (GCTs) presenting as primary CNS tumors include the full gamut of germ cell neoplasms seen as primary gonadal tumors. The majority occur either in the suprasellar region, affecting the optic nerves, chiasm, and tracts together with the hypothalamic-pituitary axis and adjacent structures, or in the pineal region, impinging on the quadrigeminal plate, the posterior third ventricle, and the posterior thalamus, although less commonly they present in other sites, notably the basal ganglia. Germ cell tumors of all types have a propensity for dissemination in the neuraxis via cerebrospinal fl uid pathways, which has historically mandated neuraxial therapies including craniospinal radiation and, more recently, systemic chemotherapy. The most common histopathologic type by far is the "pure" germinoma, a tumor composed of large primitive germ cells accompanied by abundant reactive small lymphocytes. Less common types include choriocarcinoma, yolk sac tumor/endodermal sinus tumor, and embryonal carcinoma, or combinations of any of these four histological types, often termed "teratocarcinoma" or malignant mixed GCT. Whereas in the gonads these are now all highly treatable tumors, the survival of patients with primary CNS nongerminomatous GCT remains far worse than that of patients with primary CNS germinoma. In addition to these types of tumors, there are also teratomas, which range from fully mature benign tumors ("dermoid cysts") through various grades of immature teratoma including highly malignant examples. The heterogeneity of mixed GCTs is a source for diagnostic error due to sampling. Whereas diagnosis has traditionally been dependent solely on histomorphology, the last two decades have seen the development of a wide array of immunostains for specifi c markers of GCT types; thus trophoblastic cells of choriocarcinomatous components are readily demonstrated with stains for human chorionic gonadotropin (HCG), and endodermal sinus tumor elements with stains for alpha-fetoprotein (AFP),whereas most germinoma cells are negative for these markers but are positive in stains for placental alkaline phosphatase (PLAP) or human placental lactogen (HPL). These stains provide powerful adjunctive techniques to help document the various cell types in any given example of GCT, particularly in small samples such as stereotactic biopsies, in which diagnostic histologic patterns may be obscure or absent. More recently, these immunostains have been applied to cytopathological diagnosis of cerebrospinal fl uid specimens, adding additional sensitivity and specifi city to CSF cytological diagnosis. On the horizon with the molecular revolution sweeping all of medicine including pathology is the capacity for use of in situ hybridization to identify particular interphase chromosomal abnormalities, assess expression of various receptors and other markers, and thus predict response to particular therapies.
NG11. OUR EXPERIENCE WITH CNS IMMATURE
*NP1. GENE EXPRESSION AND PRODUCTION BY CNS PURE GERMINOMAS OF HUMAN CHORIONIC GONADOTROPIN
*NP2. PATHOLOGY OF PRIMARY CNS GERM CELL TUMORS: PROGRESS AND PITFALLS
*NP3. MODERN APPROACHES TO THE DIAGNOSIS OF PRIMARY CNS GERM CELL TUMORS
T. Pietsch; Department of Neuropathology, University of Bonn Medical Center, Bonn, Germany CNS germ cell tumors represent morphological homologues of germinal neoplasms arising in the gonads or other extragonadal sites. Independent of their location, the accurate histopathological diagnosis is a main predictor for treatment response and outcome and therefore is used as a tool for patient stratifi cation. A main diffi culty in pathology is the fact that besides unalloyed forms of germinomas, embryonal carcinomas, choriocarcinoma, yolk sac tumors and teratomas, intracranial germinal neoplasms are often of mixed histologic composition. If only small biopsies are taken, the representativity of the tissue submitted for pathological review is always a point of discussion. The identifi cation of protein markers for most cell types (for example OCT4, OD30, AFP, PLAP) has clearly increased the diagnostic histological accuracy. However, although serum markers are available for yolk sac and choriocarcinomatous differentiation, these are still lacking for germinomas and embryonal carcinomas. The identifi cation of such markers will be one of the important aims of expression profi ling studies of germinomas and other GCT of the CNS. Such studies as well as genetic analysis have made quick advances after laser microdissection methods have been widely introduced in molecular pathology laboratories. Important biological pathways possibly serving as therapeutic targets have also not been identifi ed in most entities. However, in germinomas the SCF/ C-kit pathway may be crucial for tumor growth, similar to the dependency of the normal cellular counterpart of germinomas, primordial germ cells, on the pathway. In contrast to extracerebral GCTs, molecular genetic analyses are still sparse on GCT of the brain. Few data by CGH and other techniques have uncovered similarities but also differences of genetic alterations of the structural and epigenetic level. For example, by CGH and array-based technologies, genetic markers will be identifi ed capable to enrich the diagnostic toolbox for GCTs in the future. Further biological analyses will also help to pinpoint the cells of origin of the different pure and mixed GCTs.
*NP4. COEXPRESSION OF C-KIT AND SCF IN CNS GERM CELL TUMORS
H. Takeshima, H. Uchida, S. Yunoue, H. Nakamura, and J-I. Kuratsu; Kagoshima University Medical School, Kagoshima; Kumamoto University School of Medicine, Kumamoto; Japan
We have previously reported the expression of protooncogene c-kit in CNS germ cell tumors and suggested that the concentration of soluble form of c-kit (s-kit) in cerebrospinal fl uid may represent a specifi c clinical marker for germinoma-containing tumors. Here we investigated the expression of stem cell factor (SCF), a specifi c ligand of c-kit, in CNS germ cell tumor samples from 16 patients, using immunohistochemical methods to determine the expression of c-kit and SCF. The immunostaining patterns of c-kit and SCF were almost identical. In all germinoma-containing tumors, c-kit and SCF were diffusely expressed on the cell surface of germinoma cells; lymphocytes and interstitial cells were negatively stained. In immature teratomas, only mature components were immunoreactive for both c-kit and SCF. Syncytiotrophoblastic giant cells (STGCs) were negative for both SCF and c-kit. The CSF concentration of SCF was measured by sandwich ELISA to determine the possibility of tumor marker. The level of SCF also increased in germinoma, even in patients with low s-kit level. However, the specifi city of SCF seems lower than that of s-kit, since the level of SCF increased in other histological types of brain tumor, such as medulloblastoma. Therefore, a combination of s-kit and SCF may be useful for the diagnosis of germinoma. 6 Genova, Italy CNS NGGCTs are heterogenous with high proliferation, infi ltrative growth, and secretion of markers (yolk sac and choriocarcinoma elements). They are mainly located in the pineal or suprasellar area and developing in areas of subtle structures like chiasma opticum or the neurohypophysis. Therefore, it is still under discussion if a clinical diagnosis with markers (AFP/HCG) Ϯ biopsy is appropriate before starting chemotherapy or if a surgical resection should be obtained as a fi rst step. We evaluated protocol patients with CNS NGGCTs who are treated in MAKEI 89 (n ϭ 28) and in P-SIOP (n ϭ 22). Patients are evaluated for site, severe neurological symptoms at diagnosis (e.g., nerve palsies, visual impairment, and motoric dysfunction), markers, and type of surgical intervention at the beginning (clinical diagnosis Ϯ biopsy, subtotal resection, total resection). All patients are treated with comparable chemotherapy (MAKEI 89: 2 ϫ BEP/2 ϫ VIP, P-SIOP: 4 ϫ PEI) and irradiation (MAKEI 89: 50 Gy to tumor, P-SIOP: 54 Gy to tumor). In MAKEI 89, 16 patients had tumors of the pineal region, seven are located in the suprasellar region, and fi ve are in other sites. In P-SIOP, 12 cases are pineal, fi ve are suprasellar, and fi ve are elsewhere. Severe neurological symptoms are seen in 18 of 28 patients in MAKEI 89 and in 13 of 22 patients in P-SIOP. In MAKEI 89, markers are elevated in serum/CSF at diagnosis in 24 patients, whereas in P-SIOP, 20 patients have increased marker at diagnosis. Diagnosis is done clinically (Ϯ biopsy) in fi ve MAKEI 89 patients and 13 P-SIOP patients. A subtotal resection is reported in eight MAKEI 89 patients and two P-SIOP patients. A total resection is described in 13 patients from MAKEI 89 and in seven from SIOP 96. The EFS is 0.57 in MAKEI 89 (median follow-up of survivors, 120 months) and 0.68 in P-SIOP (median follow-up, 75 months). In MAKEI 89 four patients and in P-SIOP one patient died perioperatively. We conclude that although surgical techniques for diagnosis and treatment of brain tumors have been *NS6. THE ROLE OF DELAYED SURGICAL RESECTION OF PRIMARY CNS GERM CELL TUMORS H.L. Weiner; Division of Pediatric Neurosurgery, New York University School of Medicine, New York, New York, USA Germ cell tumors (GCTs) of the CNS are a rare, biologically diverse, and therapeutically controversial group of neoplasms. The unique characteristic features of these tumors, including their frequent localization to the pineal region and sensitivity to radiation therapy (RT) and chemotherapy, render them a unique model system in which to test the utility of both novel neurosurgical approaches and creative therapeutic interventions. Surgery plays an important role in the overall management of these lesions. First, endoscopic techniques have been essential in treating associated hydrocephalus, obtaining CSF for analysis, and attempting tissue diagnosis. Second, radical resection is believed to be an important initial step in the management of many pineal region lesions. However, it has become increasingly clear that resection is not recommended in the case of pure germinoma, in which no benefi t is conferred by excision, and marker-positive nongerminomatous germ cell tumor (NGGCT), which is responsive to initial chemotherapy and radiation. Experience in systemic GCTs previously revealed that residual radiographic abnormalities after initial chemotherapy often implied fi brosis or teratoma, which could be treated with delayed, second-look surgery. We (Diez et al., Childs Nerv. Syst. 15:578, 1999; Weiner and Finlay, Childs Nerv. Syst. 15:770, 1999; Sands et al., Neuro-Oncology 3:174, 2001; Weiner et al., Neurosurgery 50:727, 2002) and others reported that it is becoming acceptable to perform delayed surgery to complete the tumor response that was initiated by aggressive chemotherapy. When chemotherapy is not suffi cient to eradicate these tumors completely, a second-look operation should be considered. This approach has been incorporated into international treatment protocols. The challenge lies in recognizing pure germinoma and in determining the exact timing of delayed surgery. We found that this should be avoided in patients in whom tumor markers have not normalized completely. Moreover, in the presence of an asymptomatic mass that is not expanding, and where tumor markers are normal or decreasing, the likely diagnosis is necrosis and/or scar, and avoiding additional surgery may be possible in the risk/benefi t analysis.
*NS1. PROS AND CONS OF PREOPERATIVE NEOADJUVANT OR ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NONGERMINOMATOUS GCTS (NGGCTS): ANALYSIS OF
*NS7. ADVANCES IN NEUROSURGICAL MANAGEMENT OF PINEAL AND SUPRASELLAR REGION PRIMARY CNS GERM CELL TUMORS
M.M. Souweidane; Department of Neurological Surgery, Weill Cornell Medical College; Division of Neurosurgery, New York, New York; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; USA Surgical intervention for primary CNS germ cell tumors (GCTs) is commonly required for both diagnostic and therapeutic purposes. The deep and central location of these tumors imposes inordinate demands when conventional surgical approaches are used for tumor removal and prohibitive limitations with standard tumor biopsy methods. Fortunately, advances in surgical technology have created alternatives to conventional procedures that have truly revolutionized the surgical management of this disease. The evolution of minimally invasive endoscopic neurosurgery, heralded by advances in lens technology and light intensity, has afforded procedures that now allow exposure and tumor manipulation with minimal to no brain retraction. The pineal region, posterior third ventricle, infundibular region, suprasellar cistern, and pituitary fossa, all sites regularly affected by GCT, lend themselves to endoscopic approaches. Additionally, because of the concomitant fi nding of CSF obstruction in the majority of patients, simultaneous endoscopic procedures aimed at symptomatic relief of hydrocephalus such as endoscopic third ventriculostomy (ETV) further the appeal of an endoscopic approach. During the years of 1995 to 2005, a primary endoscopic approach has been used in the management of 86 patients, 12% (10) of whom had CNS germ cell tumors. From this group of patients, 31 primary endoscopic resections were performed and 55 endoscopic biopsies were done. Thirty-eight patients underwent a simultaneous procedure aimed at treating CSF obstruction: 18 endoscopic third ventriculostomies (ETV), 16 endoscopic septostomies, and four endoscopic tumor cyst decompressions. Endoscopic biopsy yielded a diagnostic sample in 96% (53/55) of cases, and total endoscopic tumor removal was accomplished in 90% (28/31) of cases. There were no patient deaths and four procedure-related morbidities (2 superfi cial wound infections, 1 aseptic meningitis, and 1 stroke) for a total complication rate of 4.7% and permanent morbidity rate of 1.2%. The use of endoscopic surgery in the management of intraventricular brain tumors results in an excellent diagnostic yield and a high rate of tumor removal with minimal morbidity. The anatomical position of primary CNS GCTs allows minimally invasive endoscopic procedures to be used for diagnostic purposes, tumor resection, and treatment of hydrocephalus. The safe application of these techniques is governed by rigid patient selection, the intended surgical goal, and the experience of the surgeon. The management of pineal region tumors is highly contingent upon accurate diagnosis. Pure germinomas, the most common childhood tumors in this location, are effectively treated with chemotherapy and/or radiation. However, the management of nongerminomatous germ cell tumors, pineocytomas, pineal primitive neurectodermal tumors (PNETs), and astrocytomas is more controversial, although surgical resection clearly plays a role. To ascertain the ability of preoperative diagnostic testing to determine therapy, we retrospectively reviewed the records of 50 consecutive patients with pineal region tumors treated at one institution over 10 years. This series consists of 19 germinomas, 12 nongerminomatous germ cell tumors (teratomas, embryonal carcinomas, choriocarcinomas, or germ cell tumors of mixed histology) 15 PNETs (pineoblastomas), three astrocytomas, and one pinealoma. Patients included 34 boys and 16 girls, with an age range of 6 months to 16 years (mean, 9.5 years). The preoperative MRI report included the correct histological diagnosis in the differential in 46 cases (92%). In six of the cases, the report incorrectly indicated the tumor was "likely germinoma"; however, the correct histology was mixed germ cell tumor in three cases, PNET in two, and astrocytoma in one. Serological markers (BHCG and AFP) were obtained in 44 patients (88%). These tests were normal or mildly elevated in all of the patients with germinoma, PNET, astrocytoma, or pinealoma. However, they were elevated in only fi ve of the 12 (42%) nongerminomatous germ cell tumors. Preoperative serological and radiological evaluation of pineal region tumors is not conclusive in making a histological diagnosis and could lead to inappropriate therapy. The nonsurgical standard of care in intracranial sGCTs is cisplatinumbased chemotherapy followed by radiotherapy (RT). The optimal radiotherapeutic management of localized tumors remains controversial. We reviewed the current published literature with respect to the pattern of relapse in relation to dose and volume of radiation therapy used (localized versus craniospinal). We performed a Medline search of the literature published since 1985 in the English language. Three hundred eight patients (from 1962 onward) with a median age of 12.8 years (range, 1.3-37 years) were identifi ed on the basis of histological confi rmation and/or signifi cantly raised tumor markers at diagnosis. Median follow-up was 56.9 months (range, 2-96 months). The data were analyzed according to total dose prescribed and type and dose of radiation therapy (focal versus craniospinal). Median dose prescription to the primary tumor was 48 Gy for focal RT (range, 24-60 Gy), and doses of craniospinal RT varied between 21.6 and 35 Gy with a primary tumor boost to a total dose of 50 to 60 Gy. Within the patient group, 67 relapses (21.7%) were identifi ed. The local relapse rate was 15.2%, spinal relapse rate was 5.5%, and systemic metastases rate was 0.65%, with no clear differences between patients treated with localized or extended volume RT. Patients receiving a primary tumor dose of less than 50 Gy had a 24.5% relapse rate compared to 23% in the patients treated with a higher dose. The verifi able outcome reported was better than that suggested by current preliminary data of international prospective clinical trials and is likely biased by the imprecise reporting of patterns of relapse and diffi culties of identifying individual patient outcomes in the usually very small series. We were unable to identify a clear irradiation doseresponse relationship. For localized intracranial sGCTS, there appeared to be no difference in relapse rates or pattern of relapse when treating with localized radiotherapy alone compared to craniospinal irradiation. Prospective international studies of larger patient groups are necessary to address the role of RT in sGCTs.
NS8. THE DIAGNOSTIC VALUE OF PREOPERATIVE
*RT1. DEFINING THE OPTIMAL RADIATION THERAPY FOR SECRETING CNS GERM CELL TUMORS (SGCTS):
